US Pat. No. 9,240,555

ORGANIC LUMINESCENT MATERIAL AND ORGANIC ELECTROLUMINESCENT APPARATUS

Au Optronics Corporation,...

5. An organic electroluminescent apparatus, comprising:
a first electrode layer;
a second electrode layer; and
an organic luminescent layer, located between the first electrode layer and the second electrode layer, wherein the organic
luminescent layer comprises a host luminescent material and a guest luminescent material, and the host luminescent material
comprises a compound represented by formula (1):


wherein n is 0˜8;
R2 and R3 respectively represent H, CF3, CN, CH3 or C5H11; and

R1 is one of substituents shown as follows:


US Pat. No. 9,609,786

COOLING SYSTEM FOR AN ELECTRONIC RACK

ACADEMIA SINICA, Taipei ...

1. A cooling system for an electronic rack comprising:
an electronic rack comprising at least one side wall;
at least one electronic chassis comprising a top wall and at least one side wall and disposed inside the electronic rack for
housing at least one modular electronic equipment comprising a plurality of electronic components and at least one stationary
thermal interface arranged above the plurality of electronic components;

a first detachable thermal interface arranged between the top wall of the electronic chassis and the at least one modular
electronic equipment; and

at least one second detachable thermal interface arranged between the at least one side wall of the electronic rack and the
at least one side wall of the at least one electronic chassis,

wherein the first detachable thermal interface comprises a first plate and a second plate to form a contact between each other,
wherein the first plate comprises a first oblique surface and the second plate comprises a second oblique surface to form
the contact between the first plate and the second plate.

US Pat. No. 9,353,061

3,5,N-TRIHYDROXY-ALKANAMIDE AND DERIVATIVES: METHOD FOR MAKING SAME AND USE THEREOF

ACADEMIA SINICA, Taipei ...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof;wherein:
n is 0 or 1;
represents a single or double bond;
X is carbon;
Y, Z, and U are independently carbon or nitrogen; provided that, when Y is carbon and both Z and U are nitrogen, the bond
between C6 and C7 is a double bond;

R1, R2, R3, R4, R5, and R6 are independently selected from the group consisting of null, H, C1-6 alkyl, alkenyl, alkynyl, fluoroalkyl, chloroalkyl, bromoalkyl, iodoalkyl, perfluoroalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl,
aralkyl, aralkenyl, aralkynyl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, heterocyclyl, acyl, aminocarbonyl, amino,
hydroxyl, alkoxy, acyloxy, silyloxy, amido, carbamoyl, and sulfonamido; and

R3 is optionally connected with R2 or R4 to form carbocycle or heterocycle.

US Pat. No. 9,447,193

METHODS FOR SUPPRESSING CANCER BY INHIBITION OF TMCC3

Development Center for Bi...

1. A method for treating cancer, comprising: administering to a subject in need thereof an antibody against a transmembrane
and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3, wherein
the antibody has a heavy chain and a light chain, wherein the heavy chain having complementary determination regions (CDRs)
consisting of CDRH1, CDRH2, and CDRH3, wherein the light chain having CDRs consisting of CDRL1, CDRL2, and CDRL3, wherein
CDRH1, CDRH2, and CDRH3 comprise respectively the sequences of SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, wherein CDRL1,
CDRL2, and CDRL3 comprise respectively the sequences of SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

US Pat. No. 9,115,116

DUAL ACTION INHIBITORS AGAINST HISTONE DEACETYLASES AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE

Academia Sinica, Taipei ...

1. A compound, and its pharmaceutically acceptable salt, solvate, or prodrug, in which the compound is selected from the group
consisting of:

US Pat. No. 9,411,649

RESOURCE ALLOCATION METHOD

National Taiwan Universit...

1. A resource allocation method adapted to a mobile device having a multi-core central processing unit, the central processing
unit executing at least one application, the resource allocation method comprising:
obtaining a usage status of each of the at least one application according to a level of concern of a user for each of the
at least one application;

determining a sensitivity of at least one thread of each of the at least one application according to the usage status of
each of the at least one application, wherein if the at least one application executed by the central processing unit is executed
on a background, determining the sensitivity of the at least one thread of each of the at least one application as a first
sensitivity, if the at least one application executed by the central processing unit is executed on a foreground, determining
the sensitivity of the at least one thread of each of the at least one application as a second sensitivity, and if the at
least one application executed on the foreground interacts with the user, determining the sensitivity of the at least one
thread of each of the at least one application as a third sensitivity; and

allocating resources of the central processing unit according to the sensitivity of the at least one thread run by the cores,
if the sensitivity of the at least one thread is the second sensitivity or the third sensitivity, allocating the at least
one thread to a core of the cores with a minimum total sensitivity; if the sensitivity of the at least one thread is the first
sensitivity, allocating the at least one thread to a core of the cores with a minimum total workload.

US Pat. No. 9,428,575

ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE THEREOF

Development Center for Bi...

1. An anti-granulysin antibody, or an scFv or Fab fragment thereof, wherein the antibody has the ability to neutralize an
activity of granulysin, wherein the antibody binds to epitope regions located at residues 64-67 and at residues 97-108 in
the sequence of granulysin (SEQ ID NO:79).

US Pat. No. 9,403,855

ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES

ACADEMIA SINICA, (TW)

1. A composition for inhibiting influenza virus neuraminidase, the composition comprising:
a therapeutically effective amount of at least one of the compounds:

or a pharmaceutically effective salt thereof; anda pharmaceutically acceptable excipient.

US Pat. No. 9,603,913

GLOBO H AND RELATED ANTI-CANCER VACCINES WITH NOVEL GLYCOLIPID ADJUVANTS

ACADEMIA SINICA, Taipei ...

1. An immunogenic composition, comprising:
(a) one or more glycans comprising Globo H, stage-specific embryonic antigen-3 (SSEA-3), stage-specific embryonic antigen-4
(SSEA-4), Gb4, an immunogenic fragment thereof, or combination thereof, wherein each of the glycan is conjugated with a carrier
protein selected from diphtheria toxin cross-reacting material 197 (DT-CRM 197), diphtheria toxoid, tetanus toxoid or bovine
serum albumin through a linker; and

(b) an ?-galactosyl-ceramide (?-GalCer) adjuvant, wherein the adjuvant has the following structure:

wherein the composition induces an antibody that cross-reacts with at least one of the antigens: Globo H, Gb4, SSEA-3 and
SSEA-4.

US Pat. No. 9,458,555

CHARACTERIZATION OF MICROARRAYS BY NANOGOLD STAINING

Academia Sinica, Taipei ...

1. A method for selecting a microarray suitable for performing specific binding reactions, wherein the microarray suitable
for performing the specific binding reactions meets a predetermined quality standard, the method comprising the steps of:
(a) performing a staining interaction by contacting microarrays with a solution comprising detectable cationic gold nanoparticles
under conditions, wherein biomolecules are immobilized at discrete locations on the surface of each of the microarrays, wherein
the detectable cationic gold nanoparticles are able to reversibly stain the biomolecules through an electrostatic interaction,
and wherein the conditions comprise suitable solution pH and suitable solution ionic strength for staining the biomolecules
with the cationic gold nanoparticles, thereby forming stained microarrays comprising the cationic gold nanoparticles;

(b) detecting a visible staining signal from the cationic gold nanoparticles on the stained microarrays after the staining
interaction, wherein the predetermined standard of quality is selected from the group consisting of: a stained microarray
from the stained microarrays has an uniform intensity of the visible staining signal at each of its discrete locations and
a stained microarray from the stained microarrays has an uniformity of the visible staining signal at various locations, and

(c) selecting a microarray that meets the predetermined quality standard from the stained microarrays as the microarray suitable
for performing the specific binding reactions.

US Pat. No. 9,193,665

SYNTHESIS OF GALANAL COMPOUNDS AND ANALOGUES THEREOF

Academia Sinica, Taipei ...

1. A process of preparing a compound of Formula (VI) comprising converting a compound of Formula (V) to the compound of Formula
(VI):
wherein:
GA is hydrogen, halogen, ?O, ?S, —N(R?)2, —SR?, —OR?, alkenyl, alkynyl, an amide group, an ester group, a phosphate group, an aldehyde group, a nitrile group, an
imino group, a ketone group, a thione group, an isonitrile group, an isothiocyanide group, a carbamate group, a thiocarbamate
group, or a cyclic or acyclic, substituted or unsubstituted, branched or unbranched, (hetero)aliphatic group having 1 to 6
carbon atoms, wherein R? is hydrogen, a cyclic or acyclic, saturated or unsaturated, substituted or unsubstituted, branched
or unbranched, (hetero)aliphatic group having 1 to 16 carbon atoms, an ester group, a ketone group, or a thione group;

WA is —O—, —S—, or —NR?—;

ZA is alkenyl, alkynyl, an amide group, an ester group, an aldehyde group, a nitrile group, an imino group, a ketone group, a
thione group, an isonitrile group, an isothiocyanide group, a thioate group, a thioamide, a dithioate, a carbamate group,
a thiocarbamate group, an isocyanato group, or an isothiocyanato group;

RA1, RA2, RA3, RA4, RA5, RA6, RA7, RA8, RA9, and RA10 are each independently hydrogen, halogen, or a cyclic or acyclic, substituted or unsubstituted, branched or unbranched, (hetero)aliphatic
group having 1 to 6 carbons;

RA11, RA13, RA15, and RA17 are each independently hydrogen, halogen, or a cyclic or acyclic, substituted or unsubstituted, branched or unbranched, (hetero)aliphatic
group having 1 to 6 carbon atoms;

RA12, RA14, and RA16 are each independently halogen, —N(R?)2, —SR?, —OR?, alkyl, alkenyl, alkynyl, an amide group, a carboxyl group, an ester group, an aldehyde group, a nitrile group,
an imino group, a ketone group, a thione group, an isonitrile group, an isothiocyanide group, a urea group, a carbamate group,
or a thiocarbamate group, or RA14 and RA15 are joined to form ?O or ?S;

RA18 and RA19 are each independently hydrogen, halogen, or a cyclic or acyclic, substituted or unsubstituted, branched or unbranched, (hetero)aliphatic
group having 1 to 6 carbon atoms;

RA20 is hydrogen, halogen, or a cyclic or acyclic, substituted or unsubstituted, branched or unbranched, (hetero)aliphatic group
having 1 to 6 carbon atoms; and

RA21 is hydrogen, halogen, —N(R?)2, —SR?, —OR?, alkenyl, alkynyl, an amide group, a carboxyl group, an ester group, an aldehyde group, a nitrile group, an imino
group, a ketone group, a thione group, an isonitrile group, an isothiocyanide group, a carbamate group, a thiocarbamate group,
or a cyclic or acyclic, substituted or unsubstituted, branched or unbranched, (hetero)aliphatic group having 1 to 6 carbon
atoms.

US Pat. No. 9,072,312

BIDENS PILOSA AND POLYACETYLENIC COMPOUNDS FOR PREVENTION AND TREATMENT OF COCCIDIOSIS

ACADEMIA SINICA, Taipei ...

1. A method for alleviating or treating coccidiosis in an animal in need thereof comprising administering to the animal in
need thereof a composition comprising:
(a) an animal feed; and
(b) a therapeutically effective amount of a Bidens pilosa extract or an active compound isolated from the Bidens pilosa extract to alleviate or treat the coccidiosis in the animal in need thereof, wherein the active compound isolated from the
Bidens pilosa extract is a polyacetylenic compound of formula (I):


wherein
R1 is H or CH3:

R2 is monosaccharide;

R3 is H or COCH2COOH,

m=3 or 4;
n=0 or 1;
o=1 or 2; and
p=1 or 2.

US Pat. No. 9,427,466

NANOPARTICLE-ASSISTED ULTRASOUND FOR BREAST CANCER THERAPY

Academia Sinica, Taipei ...

1. A method for reducing the growth of breast cancer cells in a subject, the method consisting of the steps:
injecting into the subject magnetic nanoparticles; and
irradiating the subject with focused ultrasound;
wherein the spatial-peak temporal-peak intensity of the ultrasound measured in a well with 1 mL water using a calibrated needle
hydrophone is less than 70 W/cm2.

US Pat. No. 9,193,687

PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS

Academia Sinica, Taipei ...

1. The compound selected from the group consisting of

US Pat. No. 9,086,416

REMOVABLE SACCHARIDE-BENZIMIDAZOLE (BIM) TAGS AND CONJUGATES THEREOF VIA 1H-POSITION OF THE BENZIMIDAZOLES

Academia Sinica, Taipei ...

1. A composition comprising a modified glycoside having the formula:
Y˜X,
wherein Y represents a monomeric or polymeric form of a saccharide, and
wherein X represents a reversibly conjugated tagging moiety comprising an N-methylated aldo-imidazole (MeIM) having the structure

wherein R?H, CH3, or a halo-atom, R??H, and wherein the R? attached to the third carbon atom from the carbon atom of the aldose conjugated
to the benzimidazole of the MeIM represents H, or a bond linking to an anomeric carbon of a monosaccharide or a polysaccharide.

US Pat. No. 9,068,823

HEIGHT MEASUREMENT BY CORRELATING INTENSITY WITH POSITION OF SCANNING OBJECT ALONG OPTICAL AXIS OF A STRUCTURED ILLUMINATION MICROSCOPE

Academia Sinica, Taipei ...

1. A method for differential height measurement of an object using structured illumination sectioning microscopy, comprising:
moving a surface of the object into a linear region of axial response curve of a microscope configured for structured illumination
sectioning microscopy, wherein the intensity of an image is linearly correlated to a height variation of the object in the
linear region of the axial response curve;

obtaining an image of the surface of the object; and
determining a profile of the surface of the object based on intensity variations in the obtained image without scanning the
object along an optical axis of the microscope.

US Pat. No. 9,562,268

RISK ASSESSMENT FOR ADVERSE DRUG REACTIONS

Academia Sinica, Taipei ...

1. A method of reducing the risk of a human patient for developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis
(TEN) induced by an anticonvulsant drug, the method comprising:
identifying a human patient in need of treatment with an anticonvulsant drug;
obtaining a genomic DNA sample from the peripheral blood of the patient;
hybridizing to the genomic DNA sample an oligonucleotide that specifically hybridizes to the HLA-B*1502 allele;
detecting the presence of the HLA-B*1502 allele in the genomic DNA sample, wherein the presence of the HLA-B*1502 allele in
the sample indicates that the patient has an increased risk of developing SJS or TEN induced by carbamazepine or phenytoin;
and;

administering to the patient an anticonvulsant drug that is not carbamazepine or phenytoin.

US Pat. No. 9,353,140

BQC-G, A TUMOR-SELECTIVE ANTI-CANCER PRODRUG

Academia Sinica, Taipei ...

1. A compound according to the formula I, below:

wherein R is a glucuronide linked via an immolative spacer, or a pharmaceutically acceptable salt thereof.
US Pat. No. 9,187,558

ANTI-EPITHELIAL CELL ADHESION MOLECULE (EPCAM) ANTIBODIES AND METHODS OF USE THEREOF

Academia Sinica, Taipei ...

1. An isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope
within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion
molecule (EpCAM, SEQ ID NO: 1).
US Pat. No. 9,085,768

APPLICATION OF THE BROCCOLI WOUND-INDUCIBLE PROMOTER OF GLUCOSE INHIBITION OF ROOT ELONGATION 1 GENE IN TRANSGENIC PLANTS

Academia Sinica, Taipei ...

1. A vector comprising a broccoli wound-inducible promoter comprising the nucleotide sequence of SEQ ID NO: 1 and a heterologous
nucleotide sequence.
US Pat. No. 9,056,077

EXTRACT OF ASPLENIUM NIDUS L

Jin Xin Biotechnology Co....

1. A method of treating prostate cancer in a subject in need thereof comprising:
administering an effective amount of an extract of Asplenium nidus L. to the subject, wherein the extract comprises:

pheophorbide a methyl ester;
1-linleoyl-3-linolenoyl-glycerol;
1-linleoyl-2,3-dipalmitoyl-rac-glycerol; and
1,3-dipalmitoyl-sn-glycerol.
US Pat. No. 9,382,330

PDIA4, TARGET OF CYTOPILOYNE DERIVATIVES, FOR TUMOR DIAGNOSIS AND TREATMENT

ACADEMIA SINICA, Taipei ...

1. A method for inhibiting growth, proliferation and/or inducing death of protein disulfide isomerase a4 (Pdia4)-overexpressed
cancer cells, comprising
(a) detecting the presence of the Pdia4-oveprxpressed cancer cells in a subject with cancer; and
(b) administering to the subject with the detected presence of the Pdia4-overexpressed cancer cells a Pdia4 inhibitor in a
therapeutically effective amount for inhibiting the growth, proliferation and/or inducing the death of the Pdia4-overexpressed
cancer cells in the subject with the cancer, wherein the Pdia4 inhibitor is selected from the group consisting of cytopiloyne,
cytopiloyne aglycone, biotinylated cytopiloyne, an Pdia4 anti-sense small interfering RNA (siRNA), and an anti-Pdia4 short
hairpin RNA (shRNA).

US Pat. No. 9,434,934

HEAT STABLE KERATINASE AND USE THEREOF

ACADEMIA SINICA, Taipei ...

1. A fusion gene comprising:
(a) a first DNA sequence encoding a protein secretion signal peptide, located at the N-terminus of the fusion gene;
(b) a second DNA sequence encoding an inhibitory domain of Meiothermus taiwanensis WR-220 keratinase, linked in translation frame with the first DNA sequence; and

(c) a third DNA sequence encoding a catalytic domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the second DNA sequence,

wherein the fusion gene is a non-naturally occurring chimeric DNA.

US Pat. No. 9,329,176

GLYCOPEPTIDE-FUNCTIONALIZED NANOPARTICLES ARRAYS FOR CAPTURING AND DETECTING BIOMOLECULES

Academia Sinica, Taipei ...

1. A surface-enhanced Raman spectroscopic (SERS) system for detecting a biomolecule, the system comprising:
a substrate,
an array of nanoparticles disposed on the substrate, each being partially embedded in the substrate and having a non-embedded
surface, and

a linking agent disposed on the non-embedded surface of each of the nanoparticles, interacting with the nanoparticle-embedded
substrate via hydrogen bonds, wherein the linking agent, a glycopeptide antibiotic capable of binding to the biomolecule,
forms a coating layer over the array of nanoparticles.

US Pat. No. 9,150,688

COPOLYMER, COMPLEX AND METHOD FOR RELEASING VIRUSES USING PH-DEPENDENCE OF THE COPOLYMER

INSTITUTE OF PHYSICS, ACA...

1. A copolymer having the following chemical formula:

wherein R1 represents aliphatic compounds or aromatic compounds, R2 includes at least one negatively charged group, n is between
20 and 30, and m is between 2 and 10.

US Pat. No. 9,124,387

DYNAMIC ADAPTION OF TRANSMISSION RATE FOR MULTIUSER MIMO NETWORKS

ACADEMIA SINICA, Taipei ...

1. A method for determination of transmission rate in a wireless communication comprising a wireless router and a plurality
of user devices, comprising the steps of:
all user devices obtain channel information of their respective communication channels from the wireless router using a reciprocity
method, when the wireless router broadcasts signals, and calculate the S/N rate (SNRori) of said channels;

a user device transmits signals to the wireless router at a transmission rate determined by SNRori;
said user device detects another user device that transmits signals to the wireless router, to obtain channel information
of the other user device;

said user device uses relation between its channel information and the channel information of the other user device to calculate
an actual S/N rate (SNRproj) of its communication channel under the influence of the other user device;

said user device uses the obtained SNRproj to adjust said transmission rate and starts to transmit signals; and
after a predetermined period time, the wireless router stops to accept data transmission from all user devices.
US Pat. No. 9,403,878

METHODS FOR PRODUCING VIRUS PARTICLES WITH SIMPLIFIED GLYCOSYLATION OF SURFACE PROTEINS

Academia Sinica, Taipei ...

1. A method for producing an immunogenic composition, the method comprising:
a) producing an influenza virus hemagglutinin (HA) antigen in an in vitro cell culture or embryonated egg with an effective
amount of a mannosidase inhibitor, wherein the concentration of the mannosidase inhibitor is sufficient to inhibit .alpha.-mannosidase
I in the N-glycosylation pathway;

b) contacting the influenza virus HA antigen recovered from step a) with endoglycosidase H (Endo H), wherein the concentration
of Endo H is sufficient to remove high mannose type glycans;

c) isolating a monoglycosylated influenza virus HA antigen produced in step b); and
d) producing an immunogenic composition comprising the monoglycosylated influenza virus HA antigen of (c) and a pharmaceutically
acceptable carrier and/or an adjuvant.

US Pat. No. 9,309,522

PHAGE DISPLAYING SYSTEM EXPRESSING SINGLE CHAIN ANTIBODY

Academia Sinica, Taipei ...

1. An isolated nucleic acid, comprising
a first nucleotide sequence encoding a signal peptide, and
a second nucleotide sequence encoding a single chain antibody capable of forming an interface disulfide bond, the second nucleotide
sequence being located 3? downstream to the first nucleotide, wherein the signal peptide has the amino acid sequence of

VKKLLX1X2X3X4X5X6X7X8X9X10AAQPAMAHHHHHHGH (SEQ ID NO:596), in which X1 is A, C, F, G, I, L, M, P, Q, S, V, W, or Y; X2 is A, D, F, G, H, I, L, M, N, P, S, T, V, or W; X3 is A, F, G, L, M, P, Q, R, S, T, V, or W; X4 is A, F, G, H, I, L, M, P, Q, R, S, T, V, W, or Y; X5 is A, C, D, F, G, H, I, L, M, P, Q, R, S, T, V, W, or Y; X6 is A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; X7 is A, C, D, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; X8 is A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y; X9 is A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W, or Y; and X10 is A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y.

US Pat. No. 9,229,012

SPECIFIC A1AT MONOCLONAL ANTIBODIES FOR DETECTION OF ENDOMETRIOSIS

Taipei Medical University...

1. A monoclonal antibody which specifically binds to an epitope of an isoform of alpha 1-antitrypsin (A1AT) having a molecular
weight of about 72 kDa or 58 kDa in a biological sample of a subject, wherein the epitope consists of an amino acid sequence
of SEQ ID NO: 3.

US Pat. No. 9,494,500

COLLECTION AND CONCENTRATION SYSTEM FOR BIOLOGIC SUBSTANCE OF INTEREST AND USE THEREOF

Academia Sinica, Taipei ...

1. A microfluidic flow-through system for enriching circulating tumor cells (CTCs) from a biologic sample, the system comprising:
a flow-through capture device comprising: (a) a sample inlet at a proximal end of the flow-through capture device configured
to receive the biologic sample at a first concentration, (b) a fluid channel fluidly coupled to the sample inlet, wherein
the fluid channel comprises one or more surfaces comprising a plurality of microstructures substantially perpendicular to
a direction of bulk fluid flow and a surface coating attached to a portion of the one or more surfaces, wherein the surface
coating comprises (1) a nonfouling lipid-bilayer composition, and (2) an antibody that selectively binds CTCs present within
the biologic sample, and (c) an outlet at a distal end of the flow-through capture device;

a three-way valve in fluid communication with the flow-through capture device, the three-way valve comprising (a) a valve
inlet fluidly coupled to the outlet of the flow-through capture device, (b) a first valve outlet for diverting away unwanted
materials, and (c) a second valve outlet, wherein the three-way valve further comprises a first state and a second state,
wherein in the first state, the three-way valve allows fluid flow from the flow-through capture device through the first valve
outlet but not the second valve outlet, and wherein in the second state, the three-way valve allows fluid flow from the flow-through
capture device through the second valve outlet but not the first valve outlet;

a flow-through concentration device in fluid communication with the three-way valve, wherein the flow-through concentration
device is configured to receive the CTCs at a second concentration higher than the first concentration and concentrate the
CTCs to a third concentration higher than the second concentration, wherein the flow-through concentration device comprises
(a) an inlet in fluid communication with the second valve outlet of the three-way valve, (b) a concentration fluid channel
comprising microfeatures arranged in a pattern that directs the CTCs towards a narrow region within the channel without directing
unwanted components towards the narrow region, (c) a single well at a distal portion of the flow-through concentration device
and within the narrow region of the channel, wherein the single well is located underneath a fluid flow path that leads towards
(d) a sample outlet, wherein the single well is configured to entrap the CTCs flowing within the narrow region of the channel
it via gravity while fluid flows over the single well via the fluid flow path towards the sample outlet, wherein a passage
leading to a base of the single well is substantially perpendicular to the fluid flow path, wherein the single well is positioned
toward a midline of the concentration device and the base of the single well has a substantially flat surface with an area
of between about 1 mm2 and about 100 mm2, and wherein the sample outlet is located at a distal end of the flow-through concentration device and is configured to allow
removal of the unwanted components from the system.

US Pat. No. 9,324,552

PERIODIC FIELD DIFFERENTIAL MOBILITY ANALYZER

Academia Sinica, Taipei ...

1. A periodic field differential mobility analyzer apparatus for separating and identifying ionic analytes, comprising:
a series of elongated parallel channels, each channel having an inlet at a first end and an outlet at a second end, each channel
enclosed between first and second parallel walls, each first wall being formed from first and second electrode plates arranged
to provide a slit opening in the first wall, each second wall being formed from third and fourth electrode plates arranged
to provide a slit opening in the second wall, wherein the first and third electrode plates enclosing a channel oppose each
other and the second and fourth electrode plates enclosing a channel oppose each other, wherein adjacent channels share electrode
plates of one wall in common, wherein the channels are in fluid communication through the slit openings in each wall, and
wherein the slit openings in each of the channels are aligned;

a pump operable to force gas in laminar flow along each of the series of parallel channels, wherein the gas flows through
and exits each channel separately and is not recirculated;

a first voltage drop applied between the first and second electrode plates of the first wall of each channel providing an
electric field Ex in a direction opposing the gas flow, wherein the first voltage drop is also applied between the third and fourth electrode
plates of the second wall;

a second voltage drop applied between the first and third electrode plates of each channel providing an electric field Ey in a direction perpendicular to the gas flow, wherein the second voltage drop is also applied between the second and fourth
electrode plates of each channel, wherein the electric fields Ex and Ey form a periodic arrangement of their combined electric field and a retarding potential wall;

an ion source arranged exterior to the channels for directing ionic analytes into an ion source slit of the wall of the channel
farthest upstream with respect to the electric field Ey, wherein the path of the ionic analytes is linear along the channels until they reach the retarding potential wall; and

a detector slit, wherein the detector slit is upstream from the ion source slit with respect to the direction of gas flow,
and wherein the slit openings in each of the channels are aligned in a predetermined angle relative to the direction perpendicular
to the walls of the channels so that the detector slit and the ion source slit are at opposite ends of the retarding potential
wall.

US Pat. No. 9,224,586

APPARATUSES AND METHODS FOR PORTABLE MASS SPECTROMETRY

Academia Sinica, Taipei ...

1. An apparatus for mass spectrometry comprising:
a. at least two mechanistically different sources of ionized analyte;
b. a mass analyzer comprising at least one ion trap having a ring electrode and two end-cap electrodes;
c. at least one frequency scanning subsystem configured to generate a constant amplitude RF trapping frequency scan in a series
of RF frequency steps, wherein during each step the RF frequency is maintained at a value for a whole integer number of cycles
and then stepped to a different RF frequency; and

d. at least one charge detector and at least one charge amplification detector;wherein the at least one ion trap is configured to operate via the RF frequency scan by applying the stepped constant amplitude
RF trapping frequency scan to the ring electrode; andwherein the apparatus has an extended mass detection range from 10 to 1016 Da.

US Pat. No. 9,074,238

METHODS FOR ENHANCING NEPRILYSIN ACTIVITY AND DEGRADING AMYLOID-BETA PEPTIDES AND OLIGOMERS IN A SUBJECT WITH ALZHEIMER'S DISEASE

ACADEMIA SINICA, Taipei ...

1. A method of enhancing neprilysin activity and/or degrading amyloid-? peptides and/or oligomers in a subject with Alzheimer's
disease, comprising:
administering to the subject a compound selected from the group consisting of
in a therapeutically effective amount to enhance the neprilysin activity and/or degrade the amyloid-? peptides and oligomers
in the subject.
US Pat. No. 9,469,854

PHARMACEUTICAL COMPOSITION FOR TREATING LIVER DISEASES

ACADEMIA SINICA, Taipei ...

1. A method for decreasing the expression of acetyl-CoA carboxylase 1 or 2 (ACACA or ACACB), diglyceride acyltransferase 2
(DGAT2), or methionine adenosyltransferase 2A or 2B (MAT2A or MAT2B) in a subject having a fatty liver disease, comprising
administering an effective amount of a microRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID NO:35)
to said subject.
US Pat. No. 9,393,316

CANCER TARGETING PEPTIDES FOR ENHANCING ANTI-CANCER DRUG DELIVERY AND THERAPEUTIC EFFICIENCIES

ACADEMIA SINICA, Taipei ...

1. A conjugate comprising:
(a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence
having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 2 and 3; and

(b) a component, to which the targeting peptide is conjugated, the component being selected from the group consisting of a
drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, liposomes, a polymer, a lipid, an oligonucleotide,
a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent.

US Pat. No. 9,387,257

LUNG CANCER SPECIFIC PEPTIDES FOR TARGETED DRUG DELIVERY AND MOLECULAR IMAGING

ACADEMIA SINICA, Taipei ...

1. A conjugate comprising:
(a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence
having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 2-8; and

(b) a component conjugated to the targeting peptide, the component being selected from the group consisting of a drug delivery
vehicle, an anti-cancer drug, a micelle, a nanoparticle, a liposome, a polymer, a lipid, an oligonucleotide, a peptide, a
polypeptide, a protein, a cell, an imaging agent, and a labeling agent.

US Pat. No. 9,321,818

DERMCIDIN-DERIVED PEPTIDES FOR LUNG CANCER DIAGNOSTICS

Academia Sinica, Taipei ...

1. A method of determining the level of a peptide biomarker E-R11 consisting of the sequence ENAGEDPGLAR (SEQ ID NO: 2) in
a test subject, the method comprising:
(a) providing a sample obtained from an exhaled breath condensate (EBC) of the test subject, wherein the sample comprises
the peptide biomarker E-R11; and

(b) detecting a level of the peptide biomarker E-R11 in the sample obtained from the exhaled breath condensate, wherein the
peptide biomarker E-R11 is a partial sequence of dermcidin (DCD; SEQ ID NO: 1).

US Pat. No. 9,067,985

BACTERIORHODOPSIN FUSION MEMBRANE PROTEIN EXPRESSION SYSTEM

ACADEMIA SINICA, Taipei ...

1. An expression vector comprising:
a) a polynucleotide sequence encoding a mutant bacteriorhodopsin having at least 80% sequence identity to SEQ ID NO: 1;
b) a multiple cloning site, located downstream from the polynucleotide encoding the mutant bacteriorhodopsin;
c) a T7 promoter, operably linked to the polynucleotide sequence encoding the mutant bacteriorhodopsin,
d) a nucleic acid sequence encoding a polyhistidine tag, located downstream from the polynucleotide sequence encoding the
mutant bacteriorhodopsin and upstream from the multiple cloning site;

e) a first polynucleic acid encoding a first protease cleavage site, located downstream from the nucleic acid sequence encoding
the polyhistidine tag and upstream from the multiple cloning site;

f) optionally a second polynucleic acid encoding a second protease cleavage site, located between the polynucleotide sequence
encoding the mutant bacteriorhodopsin and the nucleic acid sequence encoding the polyhistidine tag; and

g) optionally a nucleotide sequence encoding a linker located between the first polynucleic acid encoding the first protease
cleavage site and the multiple cloning site;
wherein the mutant bacteriorhodopsin retains Asn94 of SEQ ID NO: 1.
US Pat. No. 9,598,738

METHOD FOR PRODUCING SEGMENTAL ANEUPLOIDY (SAN) STRAINS OF TRICHODERMA REESEI VIA SEXUAL CROSSING AND SAN STRAINS PRODUCED THEREFROM

Academia Sinica, Taipei ...

1. A method for preparing a segmental aneuploid strain of Trichoderma reesei comprising steps of:
(a) identifying and choosing a first strain being Trichoderma reesei, which is mating competent and carries scaffold 33 and scaffold M in its genome;

(b) identifying and choosing a second strain being Trichoderma reesei, which is mating competent, capable of mating with the first strain of step (a), and carries scaffold F and scaffold X in
its genome;

(c) sexually crossing the first strain of step (a) with the second strain of step (b); and
(d) identifying and selecting a segmental aneuploid (SAN) progeny from step (c) that has duplication of the D segment in its
genome.

US Pat. No. 9,587,034

ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND C?MX DOMAINS

Academia Sinica, Taipei ...

1. An isolated anti-IgE antibody, which binds to the amino acid sequence SVNPGLAGGSAQS (SEQ ID NO:11).
US Pat. No. 9,493,751

DUAL-FUNCTIONAL HYBRID GLUCANASES

Academia Sinica, Taipei ...

1. A fusion polypeptide comprising:
(a) a first segment containing a TFsW203F polypeptide having residues 1-248 of SEQ ID NO:3; and

(b) a second segment containing a catalytic domain of TmLam having a sequence that is at least 90% identical to residues 211-488
of SEQ ID NO:1;

wherein the fusion polypeptide has a glucanase activity and an amino acid sequence that is at least 90% identical to the amino
acid sequence of SEQ ID NO:5 or 9.

US Pat. No. 9,478,796

GRAPHENE-CONTAINING ELECTRODES

Academia Sinica, (TW)

1. A battery, comprising:
a first electrode comprising:
a plurality of particles containing lithium;
a layer of carbon at least partially coating a surface of each of at least some of the particles; and
electrochemically exfoliated graphene at least partially coating one or more of the plurality of particles, in which the electrochemically
exfoliated graphene is produced using an electrochemical exfoliation process that includes:

immersing, in a solution containing an electrolyte, a portion of a third electrode and a portion of a fourth electrode, the
immersed portion of the third electrode including a carbon material,

causing an electric potential to exist between the third and fourth electrodes, the third electrode having a higher electric
potential than the fourth electrode, and

recovering, from the solution, graphene sheets exfoliated from the carbon material of the third electrode;
a second electrode; and
an electrolyte, wherein at least a portion of the first electrode and at least a portion of the second electrode contact the
electrolyte.

US Pat. No. 9,402,593

IMAGING OF BIOLOGICAL STRUCTURES BY CHANGING THE POSITION OR DISTANCE OF THE STRUCTURES BETWEEN A SOURCE AND A DETECTOR

Academia Sinica, Taipei ...

1. A method comprising:
inserting a contrast agent comprising objects into a blood vessel of a body, the objects having refractive indices different
from the refractive index of blood with respect to a penetrating radiation having a wavelength of 1 nm or less, the difference
in refractive indices being sufficient to provide visible edge enhancement features in images of the objects in blood vessels
that contain the objects in which the images are obtained using the penetrating radiation, the edge enhancement features being
caused by refraction of the penetrating radiation at boundaries of the objects;

placing the body on a stage wherein the stage is positioned between a penetrating radiation source and a detector;
irradiating the body including the blood vessel with the penetrating radiation having the wavelength of 1 nm or less, causing
refraction of the penetrating radiation at the boundaries of the objects, generating edge enhancement features that include
at least one of brighter or darker fringes;

adjusting a position of the body via the stage relative to the detector by moving the body from a first distance relative
to the detector to a second distance relative to the detector, in which when the body is at the first distance relative to
the detector, the edge enhancement features are less visible, and when the body is at the second distance relative to the
detector, the edge enhancement features are more visible, to cause the at least one of brighter or darker fringes produced
by the refraction of the penetrating radiation occurring at the boundaries of the objects that are inserted into the blood
vessel to be detected by the detector; and

generating an image of the objects with the blood vessels based on the detected radiation, the image including edge enhancement
features that indicate the boundaries of the objects, in which the edge enhancement features are generated based on the refraction
of the penetrating radiation at the boundaries of the objects.

US Pat. No. 9,353,422

USP37 INACTIVATION AS A TREATMENT FOR PLZF/RARA-ASSOCIATED ACUTE PROMYELOCYTIC LEUKEMIA

ACADEMIA SINICA, Taipei ...

1. A method of assaying and/or identifying a test agent as a regulator of the stability and/or the intracellular level of
the fusion protein PLZF/RARA, comprising:
(a) providing a cell comprising: (i) a first reporter protein operably linked to a tetracycline response element and the PLZF/RARA;
and (ii) a second reporter protein operably linked to an internal ribosome entry site (IRES) and the PLZF/RARA, and treating
the cell with the test agent or a vehicle control;

(b) inducing the cell to express the reporter proteins and measuring the intensity of the first reporter protein and the intensity
of the second reporter protein, and calculating the ratio of the intensity of the first reporter protein versus the intensity
of the second reporter protein in the presence and the absence of the test agent; and

(c) identifying the test agent as a positive regulator of the stability and/or the level of the fusion protein PLZF/RARA when
the ratio in the presence of the test agent is less than that in the vehicle control, or a negative regulator of the stability
and/or the level of the fusion protein PLZF/RARA when the ratio in the presence of the test agent is greater than that in
the vehicle control; or

(i) providing a cell constitutively expressing a transduced fusion protein PLZF/RARA and a transduced USP37, and treating
the cell with the test agent or a vehicle control;

(ii) measuring the amount of the PLZF/RARA in the presence and the absence of the test agent; and
(iii) identifying the test agent as a negative regulator of the stability and/or the level of the fusion protein PLZF/RARA
when the amount of the PLZF/RARA in the presence of the test agent is less than that in the vehicle control, or a positive
regulator of the stability and/or the level of the fusion protein PLZF/RARA when the amount of the PLZF/RARA in the presence
of the test agent is more than that in the vehicle control; or

(1) providing a cell constitutively expressing a transduced fusion protein PLZF/RARA and a transduced USP37, and treating
the cell with a proteasome inhibitor, which reduces the degradation of ubiquitin-conjugated proteins, and the test agent or
a vehicle control;

(2) measuring the amount of ubiquitin-conjugated PLZF/RARA within the cell in the presence and the absence of the test agent;
and

(3) identifying the test agent as a positive regulator of the stability and/or the level of the fusion protein PLZF/RARA when
the amount of the ubiquitin-conjugated PLZF/RARA in the presence of the test agent is more than that in the vehicle control,
or a negative regulator of the stability and/or the level of the fusion protein PLZF/RARA when the amount of the ubiquitin-conjugated
PLZF/RARA in the presence of the test agent is less than that in the vehicle control.

US Pat. No. 9,206,246

HEPARIN/HEPARAN SULFATE-DEPENDENT INHIBITORS OF ACTIVATED PROTEIN C AND USES THEREOF IN TREATING HEMOPHILIC DISORDERS

Academia Sinica, Taipei ...

1. A method for inhibiting activated protein C (APC), comprising contacting the APC with a Kunitz polypeptide in an amount
effective in inhibiting the activity of APC,wherein:
the Kunitz polypeptide comprises the amino acid sequence of SEQ ID NO:1.

US Pat. No. 9,190,938

PIEZOELECTRIC ACTUATING DEVICE

Academia Sinica, Taipei ...

1. A piezoelectric actuating device, comprising:
a carrier;
a first piezoelectric unit disposed on the carrier and comprising a first piezoelectric buzzer;
a second piezoelectric unit disposed on the carrier and comprising a second piezoelectric buzzer, wherein the second piezoelectric
unit is directly connected to the first piezoelectric unit;

a first linked component disposed corresponding to the first piezoelectric unit, wherein one end of the first linked component
is attached to the first piezoelectric buzzer;

a second linked component disposed corresponding to the second piezoelectric unit, wherein one end of the second linked component
is attached to the second piezoelectric buzzer; and

a moving component connected with the first linked component and the second linked component;
wherein, when one of the first piezoelectric buzzer and the second piezoelectric unit is actuated, it carries the first linked
component and the second linked component to move correspondingly so as to move the moving component.

US Pat. No. 9,144,591

TRANSCRIPTION MODULATOR COMPOSITIONS

Academia Sinica, Taipei ...

1. A method of treating benign prostate hypertrophy in a subject in need thereof, comprising administering to the subject
an effective amount of a composition containing a Wedelia chinesis extract.

US Pat. No. 9,059,408

HEXACENE DERIVATIVE, METHOD FOR FORMING HEXACENE, METHOD FOR FORMING HEXACENE CRYSTAL, PROCESS FOR MAKING ORGANIC SEMICONDUCTOR DEVICE, AND ORGANIC SEMICONDUCTOR DEVICE

Academia Sinica, Taipei ...

1. A hexacene derivative, being expressed by formula (1):
wherein each of X1 to X6 denotes presence or absence of one carbonyl bridge expressed as “—C(?O)—”, with a proviso that at least one of X1 to X6 is the one carbonyl bridge while any six-member ring absent of the one carbonyl bridge is aromatic.
US Pat. No. 9,623,077

USE OF PEPTIDE FOR ALLEVIATING PAIN

ACADEMIA SINICA, Taipei ...

1. A method for alleviating neuropathic pain in a subject in need thereof, wherein the method comprises administering an effective
amount of piscidin (PCD) peptide and a pharmaceutically acceptable carrier to the subject, wherein the PCD peptide is a PCD-1
peptide comprising the amino acid sequence of SEQ ID NO: 1.

US Pat. No. 9,484,193

AUTOMATIC AMINO ACID SEQUENCING OF GLYCOPEPTIDE BY Y1 IONS

Academia Sinica, Taipei ...

1. A mass spectrometer apparatus for glycopeptide analysis comprising:
an ionization source for creating glycopeptide analyte ions;
a quadrupole ion trap;
a linear ion trap;
a collision chamber between the quadrupole ion trap and the linear ion trap;
a pulsed valve for introducing a collision gas into the collision chamber through an elongated tube to provide a high density
molecular beam to collide with the glycopeptide analyte ions; and

a detector;wherein mass-selected glycopeptide analyte ions exit the quadrupole ion trap into the collision chamber, thereby forming glycopeptide
Y1 ions and product ions, and wherein the linear ion trap performs mass analysis of glycopeptide Y1 ions and product ions
created by higher energy collision dissociation fragmentation or collision induced dissociation fragmentation of the glycopeptide
analyte ions that have exited the quadrupole ion trap;
wherein the higher energy collision dissociation fragmentation has a normalized collision energy from 70% to 110%, based on
100 V kinetic energy as being 100% high collision energy for an m/z of 2000 and pressure of the collision gas from 10-100
mTorr.

US Pat. No. 9,387,488

MOLECULAR ENTRAPMENT AND ENRICHMENT

ACADEMIA SINICA, Taipei ...

1. A method for operating a device to aggregate particles in a fluid, comprising:
applying an ac electric field and a dc bias electric field along a channel in a device which includes:
a substrate that is electrically insulating;
an electrically insulative material formed on the substrate and structured to form the channel to carry an electrically conducting
fluid containing particles; and

a constriction structure formed of the electrically insulative material and located in the channel to narrow a channel dimension
and forming an opening with a size in the nanometer range; and

controlling the applied ac electric field and the dc bias electric field based on a structure of the constriction structure
to magnify the applied ac electric field to produce a negative dielectrophoretic force (FNDEP) in a direction away from the opening to combine with an electroosmotic force (FEO) that is caused by the applied ac electric field with the dc bias to be in the direction away from the opening to counter
an electrophoretic force (FEP) in a direction toward the opening so that the FNDEP, FEO, and FEP operate collectively to aggregate the particles in an adjacent region on a side of the opening.

US Pat. No. 9,255,130

PUF-A AND RELATED COMPOUNDS FOR TREATMENT OF RETINOPATHIES AND SIGHT-THREATENING OPHTHALMOLOGIC DISORDERS

Academia Sinica, Taipei ...

1. A method for expressing a Puf-A gene in an ocular cell, the method comprising:
providing at least a portion of a Puf-A gene suitable for expression of a Puf-A therapeutic protein;
incorporating the gene into a vector;
transfecting the vector into at least one ocular cell; and
expressing at least the portion of the therapeutic Puf-A protein in the at least one ocular cell.
US Pat. No. 9,206,431

KIT FOR PRODUCING RECOMBINANT TAG-CLEAVABLE FUSION PROTEINS VIA AT LEAST TWO DIFFERENT EXPRESSION VECTORS ALLOW PROTEIN PRODUCTION IN TWO DIFFERENT SPECIES HOST CELLS

Academia Sinica, Taipei ...

1. A kit comprising 2-6 expression vectors, each of which includes:
a first nucleic acid encoding a protein tag, and
a second nucleic acid containing (i) a nucleotide sequence that encodes a protease recognition site and (ii) one or two restriction
sites identical in all of the 2-6 expression vectors for cloning a target gene that encodes a target polypeptide,

wherein each of the expression vectors allows in a host cell production of a fusion protein including the protein tag, the
protease recognition site, and the target polypeptide, which is separable from the protein tag via protease cleavage at the
protease recognition site; and at least two of the expression vectors allow protein production in two different host cells,
which are selected from the group consisting of an E. coli host cell, a yeast host cell, an insect host cell, and a mammalian host cell, and

wherein the second nucleic acid includes the nucleotide sequence of GAGAACCTGTACGTACAG (SEQ ID NO: 1), which encodes a TEV
protease recognition site and includes an SnaB I site used for cloning the target gene.

US Pat. No. 9,150,655

ANTI-C-MET ANTIBODY AND METHODS OF USE THEREOF

ACADEMIA SINICA, Nankang...

1. An isolated monoclonal antibody that binds to human c-Met, comprising:
a heavy chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:10; as a CDR2 the
sequence of SEQ ID NO:12, and as a CDR3 the sequence of SEQ ID NO:22; and

a light chain variable region wherein the variable region comprises as a CDR1 the sequence of SEQ ID NO:31, as a CDR2 the
sequence of SEQ ID NO:33, and as a CDR3 the sequence of SEQ ID NO:43.

US Pat. No. 9,121,021

REDUCING GALECTIN-12 ACTIVITY TO INFLUENCE THE CELL FUNCTION OF HUMAN SEBOCYTES

ACADEMIA SINICA, Taipei ...

1. A method for the treatment of acne or a sebaceous gland disorder, or both, comprising:
administering to a subject in need of treating the acne or sebaceous gland disorder, or both a therapeutically effective amount
of a pharmaceutical composition comprising:

(a) a non-naturally occurring, small molecule inhibitor of galectin-12, or a non-naturally occurring nucleic acid-based inhibitor
targeted to galectin-12; and

(b) a pharmaceutically acceptable carrier,
wherein the sebaceous gland disorder is selected from the group consisting of sebaceous hyperplasia, sebaceous gland carcinoma,
atopic dermatitis, seborrheic dermatitis and primary cicatricial alopeci.

US Pat. No. 9,340,812

LARGE SCALE ENZYMATIC SYNTHESIS OF OLIGOSACCHARIDES

Academia Sinica, Taipei ...

1. A method for enzymatically synthesizing an oligosaccharide, comprising:
(i) producing UDP-Gal from galactose in the presence of a set of UDP-Gal regeneration enzymes, wherein the set of UDP-Gal
regeneration enzymes comprises a galactokinase, an UDP-sugar pyrophosphorylase, and a pyruvate kinase;

(ii) converting Lactose-OR1A into Globotriose-OR1A (Gb3-OR1A) in the presence of the UDP-Gal and an alpha-1,4 galactosyltransferase, wherein R1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, or an oxygen protecting group;

(iii) converting the Gb3-OR1A into Globotetraose-OR1A (Gb4-OR1A) in the presence of UDP-GalNAc and a beta-1,3-N-acetylgalactosaminyltransferase; and

(iv) converting the Gb4-OR1A into Globopentaose-OR1A (Gb5-OR1A) in the presence of UDP-Gal and a beta-1,3-N-galactosyltransferase,

wherein the method is performed without purifying intermediates,
wherein the method is performed with all enzymes free of cells.

US Pat. No. 9,267,927

ROBUST AND LOW BACKPRESSURE ON-COLUMN TUNNELED FRIT FOR NANO-UPLC-MS APPLICATIONS

Academia Sinica, Taipei ...

1. The combination of a capillary column adapted to retain a stationary packing and a tunneled fit adhered to the column at
one end thereof, the combination being suitable for use in a liquid chromatography (LC) and in capillary electrophoresis chromatography
systems and for nanoflow and microflow operations, wherein said tunneled fit contains a tunnel in open communication between
the inside and outside of said column, and wherein the tunnel is not sealed while under pressures of up 12,000 psi when performing
the LC, capillary electrophoresis chromatography, and nanoflow and microflow operations, and wherein the tunneled fit is made
by the process of:
providing a capillary column;
inserting a heat resistant wire a predetermined distance into said column;
contacting said column with an uncured material capable of bonding to the column and causing the uncured material to penetrate
into the column not further than the depth of the wire;

removing the wire when the uncured material is set; then
further curing the material to create a high pressure resistant bond of the resulting tunneled frit and the column.

US Pat. No. 9,073,941

COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION

Academia Sinica, Taipei ...

1. A method of treating a tuberculosis infection, the method comprising administering an effective amount of a compound of
Formula (III) or (IV):
or a pharmaceutically acceptable salt thereof, to a subject in need thereof;wherein:
each of R6, R7, and R8, independently, is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl;

each of R9 and R10, independently, is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted
heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, halo, nitro, —CN, —ORa, —COORa, —OC(O)Ra, —C(O)Ra, —C(O)NRbRc, or —NRbRc;

each instance of Ra is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl,
optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally
substituted heteroaryl;

each instance of Rb and Rc is, independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl,
optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally
substituted heteroaryl, an amino protecting group, or Rb and Rc, together with the nitrogen atom to which they are bonded are an optionally substituted heterocycloalkyl, an optionally substituted
heterocycloalkenyl, or an optionally substituted heteroaryl;

m is 0, 1, or 2; and
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9.
US Pat. No. 9,173,868

USE OF DEOXYELEPHANTOPIN (DET) AND ANALOGUES THEREOF FOR REDUCING SIDE EFFECTS OF AN ANTI-CANCER AGENT

Academia Sinica, Taipei ...

1. A method of reducing side effects of an anti-cancer agent in a subject in need thereof, comprising:
administering to the subject, who is under an anti-cancer agent treatment, a composition comprising:
(a) a therapeutically effective amount of isolated deoxyelephantopin, isodeoxyelephantopin, scabertopin, isoscabertopin, or
any combination thereof; and

(b) a pharmaceutically acceptable carrier,
wherein the anti-cancer agent is at least one anti-melanoma agent selected from the group consisting of cisplatin, betulinic
acid, 4-S-cysteaminyl catechol, 4-S-cysteaminyl phenol, everolimus, bortezomib, paclitaxel, carboplatin, dacarbazine, celecoxib,
temozolomide, sorafenib, thalidomide, lenalidomide, oxaliplatin, docetaxel, valproic acid, vinblastine, imatinib mesylate,
bosentan, doxorubicin, apomine, arsenic trioxide, carmustine and tamoxifen.

US Pat. No. 9,459,247

QUANTITATIVE MEASUREMENT OF NANO/MICRO PARTICLE ENDOCYTOSIS WITH CELL MASS SPECTROMETRY

Academia Sinica, Taipei ...

1. A method for quantifying a number of nanoparticles taken up by an individual cell, the method comprising the steps of:
(a) contacting a cell with a nanoparticle of dimension less than 1 ?m, under conditions suitable for uptake of the nanoparticle
by the cell, and incubating for a specific period of time;

(b) recording a mass spectrum of the cell by cell mass spectrometry, wherein the process of cell mass spectrometry comprises:
mounting and desorbing/vaporizing the cell into a gas phase;
enhancing the number of charges on the cell;
measuring a mass to charge (m/z) ratio by a mass analyzer; and
measuring the total number of charges (z) on the cell by a charge detector coupled to the mass analyzer;
(c) measuring a mass/charge (m/z) ratio of the cell contacted with the nanoparticle and a mass/charge (m/z) ratio of a corresponding
cell not contacted with the nanoparticle;

(d) measuring an absolute mass of each cell with an uptake of nanoparticles from the acquired values of m/z and the corresponding
charge (z) on the cell, wherein the cell with an uptake of the nanoparticles shows an upward shift in m/z ratio; and

(e) measuring the number of nanoparticles taken up by the individual cell within the specific period of time from a mean mass
difference, wherein a mass difference corresponding to a known number of the nanoparticle of a known dimension is predetermined
as a standard.

US Pat. No. 9,096,800

SUPERTORREFACTION OF BIOMASS INTO BIOCOAL

Academia Sinica, Taipei ...

1. A supertorrefaction system comprising:
a plurality of pools including at least one supertorrefying pool containing molten salt as a liquid heat transfer agent that
is in direct contact with the biomass and that converts the biomass into biocoal, and at least one wash pool containing salty
wash water that is in direct contact with the biocoal and that cools the biocoal, dissolves and removes the salt attached
to the biocoal; and

a conveyor system transporting the biomass through the plurality of pools in a first direction while transporting the biocoal
in a second direction opposite to the first direction.

US Pat. No. 9,541,480

CAPTURE, PURIFICATION, AND RELEASE OF BIOLOGICAL SUBSTANCES USING A SURFACE COATING

Academia Sinica, Taipei ...

1. A method comprising:
(a) contacting a biological sample comprising rare cells and non-specific cells to a non-fouling lipid layer of a microfluidic
device, the microfluidic device comprising an antibody which selectively binds to rare cells, and wherein the non-fouling
lipid layer is non-covalently associated with the antibody;

(b) binding the rare cells to the antibody;
(c) washing the non-fouling lipid layer with a liquid, wherein the non-specific cells in contact with the non-fouling lipid
layer are released from the non-fouling lipid layer; and

(d) flowing a liquid comprising bubbles through a channel of the microfluidic device of step (c), thereby releasing the rare
cells from the microfluidic device.

US Pat. No. 9,228,196

METHOD FOR CHANGING NITROGEN UTILIZATION EFFICIENCY IN PLANTS

Academia Sinica, Taipei ...

1. An isolated nucleic acid molecule, comprising a nucleic acid sequence encoding a chimera nitrate transporter protein that
has the amino acid sequence of SEQ ID NO:11.

US Pat. No. 9,138,476

NANOPARTICLE-ASSISTED ULTRASOUND FOR CANCER THERAPY

Academia Sinica, Taipei ...

1. A method for reducing the growth of adenocarcinomic lung cancer tumor cells in a subject, the method consisting of the
steps:
injecting gold nanoparticles into the subject; and
irradiating the subject with focused ultrasound,
wherein the spatial-peak temporal-peak intensity of the ultrasound measured in a well with 1 mL water using a calibrated needle
hydrophone is less than 70 W/cm2.

US Pat. No. 9,340,794

METHOD FOR ORDERING AND INTRODUCING MULTIPLE GENES INTO A GENOME

Academia Sinica, Taipei ...

1. A method of inserting a plurality of nucleic acid molecules in a predetermined order into a predetermined site in the genome
of a cell, the method comprising,
providing a plurality of nucleic acid molecules to be inserted into a predetermined site in the genome of the cell in a predetermined
order next to each other, the plurality of nucleic acid molecules including a first nucleic acid molecule in the order, a
last nucleic acid molecule in the order and at least one intervening nucleic acid molecule to be inserted between the first
and last nucleic acid molecules, wherein each of the plurality of nucleic acid molecules contains (a) a nucleic acid sequence
operatively linked to a promoter sequence at the 5? end of the nucleic acid molecule, and (b) an overlapping sequence at the
3? end of the nucleic acid molecule, the promoter sequence in each nucleic acid molecule being different, wherein the overlapping
sequence in the at least one intervening nucleic acid molecule is homologous to a portion of a promoter sequence in an adjacent
nucleic acid molecule and a portion of the promoter sequence in the at least one intervening nucleic acid molecule is homologous
to the overlapping sequence in another adjacent nucleic acid molecule, and wherein a portion of the promoter sequence of the
first nucleic acid molecule is homologous to a first sequence in the predetermined site and the overlapping sequence of the
last nucleic acid molecule is homologous to a second sequence in the predetermined site; and

introducing the plurality of nucleic acid molecules simultaneously into the cell, whereby the plurality of nucleic acid molecules
join together in the predetermined order via homologous recombination between the overlapping sequences and the promoter sequences,
and are inserted into the genome via homologous recombination between the promoter sequence of the first nucleic acid molecule
and the first sequence in the predetermined site and between the overlapping sequence of the last nucleic acid molecule and
the second sequence in the predetermined site.

US Pat. No. 9,186,356

METHODS FOR TREATING FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITINATED INCLUSIONS (FTLD-U)

Academia Sinica, Taipei ...

1. A method of alleviating and/or rescuing a motor function deficit associated with frontotemporal lobar degeneration with
ubiquitinated inclusions (FTLD-U) comprising:
administering to an animal in need of alleviating and/or rescuing the motor function deficit associated with frontotemporal
lobar degeneration with ubiquitinated inclusions (FTLD-U) a therapeutically effective amount of rapamycin, and thereby alleviating
and/or rescuing the motor function deficit associated with the FTULD-U, wherein the animal has an early stage of frontotemporal
lobar degeneration without exhibiting ubiquitinated inclusions in the forebrain thereof.

US Pat. No. 9,555,412

NANOFLUIDIC DEVICES FOR SINGLE-MOLECULE ANALYSIS OF PROTEIN-DNA COMPLEX

ACADEMIA SINICA, Taipei ...

1. A device for optical mapping of protein binding sites, comprising:
an insulating substrate, comprising two parallel channels and at least one slit connecting the two parallel channels;
a coverslip on the insulating substrate;
at least two reservoirs on the substrate connecting the two parallel channels of the insulating substrate, wherein one of
the at least two reservoirs is formed from acrylic material; and

at least two electrodes in the at least two reservoirs so that when the at least two reservoirs are filled with a buffer solution,
the at least two electrodes are in electrical contact in the buffer solution.

US Pat. No. 9,226,951

ANTI-TUMOR FIBRILLAR HUMAN SERUM ALBUMIN METHODS AND COMPOSITIONS

ACADEMIA SINICA, Taipei ...

1. A composition comprising:
fibrillar human serum albumin and a pharmaceutically acceptable carrier wherein the human serum albumin is produced by a method
comprising:

dissolving human serum albumin in a suitable detergent
sonicating the human serum albumin
applying the sonicated human serum albumin to a gel filtration column with a separation range above 70 kDA molecular weight;
so as to promote column-induced fibrillar protein formation and to separate globular protein from fibrillar protein;

eluting the fibrillar human serum albumin from the column with a buffer containing a low concentration of detergent;
collecting eluent containing fibrillar human serum albumin from the column, and
dialyzing the eluent to remove the detergent.

US Pat. No. 9,662,080

METHOD OF TRACKING SPECIFIC CELLS IN VIVO

ACADEMIA SINICA, Taipei ...

1. A method of tracking specific cells in vivo, comprising:
providing a plurality of fluorescent nanoparticles suitable for targeting specific cells;
administering the plurality of fluorescent nanoparticles to a subject, wherein the plurality of fluorescent nanoparticles
comprises Gd2O3, Y3Al5O12, Y2SiO5, ZnO, BaMgAl14O23, Ti2O3, Zn2SiO2, Cn2SiO4, BaSiO4, or (Y,Gd)BO3;

providing an X-ray source to irradiate the subject, wherein an X-ray image of the subject irradiated by the X-ray source is
produced and the plurality of fluorescent nanoparticles are also stimulated by the X-ray source to emit fluorescence; and

determining the growth and distribution of the specific cells by the fluorescence emitted by the plurality of fluorescent
nanoparticles in the subject irradiated by the X-ray source and observing the growth and distribution of a capillary in vivo
by the X-ray image of the subject irradiated by the X-ray source, wherein in the X-ray image of the subject irradiated by
the X-ray source, the distribution of the capillary is revealed by the plurality of fluorescent nanoparticles.

US Pat. No. 9,075,245

OPTICAL MODULE FOR X-RAY MICROSCOPE

ACADEMIA SINICA, Nankang...

1. An optical module, comprising:
at least a carrying stage having a first aperture;
at least an actuator unit disposed at one side of the carrying stage and having a second aperture; and
at least an optical assembly connected with the actuator unit, wherein the actuator unit adjusts a position of the optical
assembly, and a radiated wave enters from one side of the optical module and passes through the first aperture, the second
aperture and the optical assembly.

US Pat. No. 9,821,017

EXTRACT OF ASPLENIUM NIDUS L

Jin Xin Biotechnology Co....

1. A method of treating benign prostate hyperplasia in a subject in need thereof comprising:
administering an effective amount of an extract of Asplenium nidus L. to the subject, wherein the extract comprises:

pyropheophorbide a methyl ester;
pheophorbide a methyl ester;
1-linleoyl-3-linolenoyl-glycerol;
1-linleoyl-2,3-dipalmitoyl-rac-glycerol; and
1,3-dipalmitoyl-sn-glycerol.

US Pat. No. 9,696,391

HIGH SPEED SAMPLE TRANSPORTATION APPARATUS IN A SUPERCONDUCTING MAGNET AND TRANSPORTING METHOD THEREOF

ACADEMIA SINICA, Taipei ...

1. A shuttling device for transporting a sample into and out a space inside a superconducting magnet, comprising:
a base fixed above the superconducting magnet, said base attached to a motor and a driving pulley;
a rail block extending from the base to the space, and having a belt track along the rail block and a turning pulley at the
end of the rail block;

a flexible belt which is disposed along the belt track and engaged with the driving pulley and the turning pulley; and
at least two guiding rods adjacently disposed to the belt track having a shuttle capable of holding the sample;
wherein the shuttle is configured to travel between the at least two guiding rods and is engaged by a coupler with the flexible
belt to move the shuttle along the rail block between the space within the superconducting magnet to a zone at or beyond the
fringe of the magnetic field.

US Pat. No. 9,884,207

DETECTOR FOR MEASURING SCANNING ION BEAMS IN RADIATION THERAPY

Academia Sinica, Taipei ...

1. A detector for measuring scanning ion beams in radiation therapy, comprising:
a first high voltage electrode, comprising a first high voltage region and a first grounded region surrounding the first high
voltage region;

a second high voltage electrode, comprising a second high voltage region and a second grounded region surrounding the second
high voltage region;

a dual-sided segmented electrode, disposed between the first high voltage electrode and the second high voltage electrode,
comprising a first detection region disposed correspondingly to the first high voltage region, a second detection region having
a rear side facing the first detection region and disposed correspondingly to the second high voltage region, a third grounded
region surrounding the first detection region and the second detection region, a first reading electrode disposed in the first
detection region, and a second reading electrode disposed in the second detection region;

a first spacing member, disposed between the first high voltage electrode and the dual-sided segmented electrode, comprising
a first frame body connected to the first grounded region and the third grounded region, and a first ionization cavity formed
by the first frame body surrounding the first high voltage region and the first detection region, the first reading electrode
being accommodated in the first ionization cavity; and

a second spacing member, disposed between the second high voltage electrode and the dual-sided segmented electrode, comprising
a second frame body connected to the second grounded region and the third grounded region, and a second ionization cavity
formed by the second frame body surrounding the second high voltage region and the second detection region, the second reading
electrode being accommodated in the second ionization cavity.

US Pat. No. 9,662,324

METHODS AND COMPOSITIONS FOR TREATING ?-THALASSEMIA AND SICKLE CELL DISEASE

Academia Sinica, Taipei ...

1. A method of inducing ? globin production, comprising:contacting a cell with an effective amount of a compound of formula (I-a):

or a pharmaceutically acceptable salt thereof,
wherein:
R1, R2, R3, R4, R6a, and R6b are each independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted
alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally
substituted aryl, —ORA, —OC(O)RA, —SRA, —N(RB)2, —N(RA)C(O)RA, —C(O)N(RB)2, —CN, —NO2, —C(O)RA, —C(O)ORA, —S(O)RA, —SO2RA, —SO2N(RB)2, and —NHSO2RB;

R5 is hydrogen, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, optionally
substituted heteroaryl, or optionally substituted aryl, unsubstituted alkyl, or alkyl substituted with halogen, —ORA, —N(RB)2, —C(?O)ORA, a monocyclic or bicyclic aryl aromatic ring system with 6-10 carbon atoms, wherein at least one ring is aromatic, —CHO,
—CN, or —NO2;
each instance of RA is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted
aryl; and

each instance of RB is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, and optionally substituted
aryl, or two RB are taken together with the intervening atoms to form a heterocycle.

US Pat. No. 9,610,268

TRANS-ACONITIC ACID COMPOUNDS AND USES THEREOF FOR INHIBITING PHOSPHODIESTERASE 7

Academia Sinica, Taipei ...

1. A method for treating a subject having a disease associated with dysregulation of a phosphodiesterase 7 (PDE7), comprising:
administering a composition comprising trans-aconitic acid to the subject in an amount of 0.1 ?g/Kg to 100 mg/Kg inhibit the
activity of the PDE7 in the subject.
US Pat. No. 9,777,273

SMALL INTERFERING RNA AND PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING GALECTIN-12 EXPRESSION AND/OR ENHANCING LIPOLYSIS CONTAINING THE SAME

INDUSTRIAL TECHNOLOGY RES...

1. A small interfering RNA (siRNA), consisting of a passenger strand and a guide strand,
wherein the sequence of the passenger strand comprises the sequence of SEQ ID NO. 7, and the sequence of the guide strand
comprises the sequence of SEQ ID NO. 8,

wherein the small interfering RNA is capable of inhibiting galectin-12 expression.
US Pat. No. 9,770,485

METHODS FOR RESCUING LEARNING AND/OR MEMORY DEFICITS CAUSED BY ALZHEIMER'S DISEASE BY G-CSF

Academia Sinica, Taipei ...

1. A method of rescuing learning and/or memory deficits caused by Alzheimer's disease, comprising:
(a) administering to a subject suffering from the learning and/or memory deficits caused by the Alzheimer's disease granulocyte-colony
stimulating factor (G-CSF) in an effective amount to rescue the learning and/or memory deficits caused by the Alzheimer's
disease in the subject; and

(b) testing the subject for learning and/or memory performance.
US Pat. No. 9,803,179

MUTANT CYANOBACTERIA AND METHOD TO ENHANCE PHOTOSYNTHETIC GROWTH AND BIOMASS PRODUCTION OF CYANOBACTERIA

Academia Sinica, Taipei ...

1. A mutant Synechocystis cell, expressing a mutant Synechocystis cytochrome polypeptide selected from the group consisting of:
(a) a mutant Synechocystis cytochrome b559 ? polypeptide, which has alanine (A) at the position corresponding to position S23 in SEQ ID NO: 1;

(b) a mutant Synechocystis cytochrome b559 ? polypeptide, which has (i) alanine (A) or valine (V) at the position corresponding to position S28 in SEQ
ID NO: 2, or (ii) phenylalanine (F) at the position corresponding to position V32 in SEQ ID NO: 2; and

(c) a mutant Synechocystis cytochrome PsbJ polypeptide, which has (i) phenylalanine (F) or arginine (R) at the position corresponding to position A16
in SEQ ID NO: 3, or (ii) phenylalanine (F) at the position corresponding to position A20 in SEQ ID NO: 3.

US Pat. No. 9,725,736

MUTANT GIBBERELLIN 2-OXIDASE GENES AND USES THEREOF

Academia Sinica, Taipei ...

1. An isolated polynucleotide that encodes a mutant class C20 gibberellin 2-oxidase protein (C20 GA2ox), wherein the mutant C20 GA2ox protein includes an amino acid mutation selected from the group consisting of:
(i) an amino acid residue corresponding to position 123 of SEQ ID NO: 1 substituted with Alanine (123A),
(ii) an amino acid residue corresponding to position 140 of SEQ ID NO: 1 substituted with Alanine (140A),
(iii) an amino acid residue corresponding to position 141 of SEQ ID NO: 1 substituted with Glutamate (141E),
(iv) an amino acid residue corresponding to position 143 of SEQ ID NO: 1 substituted with Alanine (143A), and
(v) an amino acid residue corresponding to position 343 of SEQ ID NO: 1 substituted with Alanine (343A).
US Pat. No. 9,695,463

DNA 5-METHYL CYTOSINE DEMETHYLATION ACTIVITY OF VERTEBRATE DNA METHYLTRANSFERASES

ACADEMIA SINICA, Taipei ...

1. A method for identifying a test agent as a modulator of the active DNA demethylation activity of a DNA methyltransferase,
comprising:
(a) providing a methylated DNA;
(b) providing the DNA methyltransferase;
(c) allowing the methylated DNA to react with the DNA methyltransferase in the presence of calcium ions for a sufficient time
to perform a demethylation reaction and generate a demethylated DNA product in the presence or absence of a test agent;

(d) analyzing the extent of demethylation; and
(e) comparing the extents of the demethylation in the presence and absence of the test agent, and thereby identify the test
agent as a modulator of the DNA demethylation activity of the DNA methyltransferase;

wherein the test agent is identified as an inhibitor of the active DNA demethylation activity of the DNA methyltransferase
when the extent of the demethylation is less in the presence of the test agent; or the test agent is identified as a stimulator
of the active DNA demethylation activity of the DNA methyltransferase when the extent of demethylation is more in the presence
of the test agent.

US Pat. No. 9,737,570

METHOD AND COMPOSITION OF INDUCING HAIR FOLLICLE NEOGENESIS

National Taiwan Universit...

1. A method of inducing hair follicle neogenesis in the skin of a subject in need thereof, comprising the steps of:
a. providing a skin extract, wherein the skin extract is obtained from mincing and mixing a skin tissue derived from the subject
with phosphate buffer solution (PBS) to form a skin tissue solution, thawing the skin tissue solution after overnight freeze;

b. mixing the skin extract with a cell to form a mixture, wherein the cell is a epithelial cell or a fibroblast derived from
the subject; and

c. transplanting the mixture into the subject.

US Pat. No. 9,754,328

SOCIAL ACTIVITY PLANNING SYSTEM AND METHOD

ACADEMIA SINICA, Taipei ...

1. A social activity planning system, comprising:
a database storing a plurality of candidate invitees, geographical locations of the candidate invitees, interest scores towards
a topic of the candidate invitees, and a social graph (G={V,E}) comprising vertices (vi ? V) representing the candidate invitees, and edges (ei,j ? E) connecting vertex (vi) and vertex (vj) representing mutual acquaintance of the candidate invitees represented by the vertex (vi)and the vertex (vj); and

a social activity planning device connected to the database, comprising a processing unit and an input unit, wherein the input
unit receives a social activity request comprising an invitation number (P), information about a social activity, and a familiarity
condition for the social activity request, and the processing unit finds a feasible solution, wherein the feasible solution
comprises (p) candidate invitees and meets the familiarity condition, and

wherein the information about a social activity request comprises a rally point location (q), the familiarity condition comprises
a familiarity constraint number (k), and the processing unit finds the feasible solution by performing the following operations:

(a) packing the candidate invitees in an R-tree data structure with tree nodes in the R-tree data structure representing the
candidate invitees or minimum bounding rectangles (MBRs) of the candidate invitees if the R-tree data structure has not been
constructed;

(b) generating a priority queue according to the tree data structure with the priority queue in ascending order based on the
distance of the geographical locations of the candidate invitees to the rally point location (q);

(c) running backtracking algorithm with a branch-and-bound tree to move candidate invitees from a first set (SR) to a second set (SI) according to the priority queue, wherein the first set (SR) comprises all the candidate invitees at initialization, the candidate invitees moved to the second set (SI) are intermediate candidate invitees, and tree nodes in the branch-and-bound tree representing the second set (SI) comprising different intermediate candidate invitees; and

(d) generating the feasible solution wherein the feasible solution is obtained when the backtracking algorithm first expands
the branch-and-bound tree to the second set (SI) comprising (p) intermediate candidate invitees, and meeting the familiarity condition, which means an average number of
unknown intermediate candidate invitees of the intermediate candidate invitees in the second set (SI) does not exceed the familiarity constraint number (k).

US Pat. No. 9,718,891

ANTIBODIES SPECIFIC TO A NOVEL EPITOPE ON C?MX OF HUMAN MEMBRANE-BOUND IGE AND USES THEREOF IN TREATING IGE-MEDIATED DISEASES

Academia Sinica, Taipei ...

1. An isolated anti-IgE antibody that binds to AAGGSVPHPRCHCGAGRA (SEQ ID NO:1).
US Pat. No. 9,763,431

TILAPIA (OREOCHROMIS NILOTICUS) MYOSIN LIGHT CHAIN 3 PROMOTER

ACADEMIA SINICA, Taipei ...

1. A construct comprising a Mlc3 promoter comprising the nucleotide sequence of SEQ ID NO. 1 and fused to a nucleotide sequence
coding for a target protein, wherein the target protein is a luciferase protein.
US Pat. No. 9,797,015

GENETIC VARIANTS ASSOCIATED WITH LITHIUM RESPONSE IN BIPOLAR DISORDER

Academia Sinica, Taipei ...

1. A method of detecting a glutamate decarboxylase-like 1 (GADL1) gene variant in a bipolar disorder patient, the method comprising:
obtaining a sample from a patient having bipolar disorder; and
assaying the sample to detect one or more GADL1 gene variants selected from the group consisting of:
(i) a T allele of the single nucleotide polymorphism (SNP) rs17026688;
(ii) a G allele of the SNP rs17026651; and
(iii) GADL1 IVS8+48delG.

US Pat. No. 9,822,140

METHODS AND INTERMEDIATES FOR THE PREPARATION OF FONDAPARINUX

Academia Sinica, Taipei ...

1. A compound of Formula (I):

wherein:
X1 is —ORA or —SRA, wherein RA is hydrogen, an oxygen or sulfur protecting group, optionally substituted C1-10 alkyl, optionally substituted aryl, optionally substituted acyl, or optionally substituted imidoyl;

R2 and R11 are independently optionally substituted arylalkyl;

RN1, RN2, and RN3 are independently —N3 or —N(RW)2, wherein each RW is independently hydrogen or a nitrogen protecting group;

R3 and R6 are independently —C(O)RD, wherein each occurrence of RD is independently optionally substituted alkyl or optionally substituted aryl;

R1, R5, and R9 are independently selected from the group consisting of optionally substituted arylalkyl and —Si(RB)3, wherein each RB is independently alkyl or aryl;

R10 is optionally substituted arylalkyl;

RY and RZ are independently hydrogen or an oxygen protecting group;

R7 is selected from the group consisting of —Si(RB)3, optionally substituted arylalkyl, and —C(O)RC, wherein RC is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and

R4 and R8 are independently optionally substituted arylalkyl;

or a salt thereof.

US Pat. No. 9,782,476

HUMAN INKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS

ACADEMIA SINICA, Taipei ...

1. A human immune adjuvant compound having Formula (I):

or a pharmaceutically acceptable salt thereof;
wherein:
R1 is —OH;

R2 is —OH;

R3 is hydrogen;

R4 is selected from the group consisting of optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted
heterocyclyl, optionally substituted heteroaryl, optionally substituted alkoxy, an optionally substituted amino group, and
optionally substituted acyl;

R5 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl,
optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl,
optionally substituted heteroaryl, optionally substituted alkoxy, an optionally substituted amino group, and optionally substituted
acyl;

n is an integer of 1 to 15, inclusive; and
m is an integer of 1 to 20, inclusive.
US Pat. No. 9,771,589

TREATING HEPATITIS VIRUS INFECTION BY MODULATING MICRORNAS MIR-130A, MIR-130B, MIR-204, OR MIR-1236

Academia Sinica, Taipei ...

1. A method of inhibiting replication of hepatitis B virus (HBV), the method comprising contacting liver cells infected with
HBV with a miR-130a RNA, a miR-130b RNA, a miR-204 RNA, a miR-1236 RNA, or a combination thereof in an amount effective for
inhibiting replication of the HBV, whereby HBV replication in the liver cells is inhibited.

US Pat. No. 9,816,981

ALKYNYL SUGAR ANALOGS FOR LABELING AND VISUALIZATION OF GLYCOCONJUGATES IN CELLS

ACADEMIA SINICA, Taipei ...

1. A composition comprising a tagged glycoconjugate wherein the tagged glycoconjugate is linked to a probe through a triazole
moiety wherein the tagged glycoconjugate is provided by a process comprising:
a) providing the L-enantiomer of the alkynyl derivatized sugar 1 having the structure

b) metabolically incorporating the alkynyl derivatized sugar 1 into a cellular glycan of a cell via the Fuc salvage pathway
thereby producing a tagged glyconjugate in the cell wherein the tagged glycoconjugate comprises a glycan portion, a conjugate
portion from the cellular glycan and the alkyne functional group from the alkyne derivatized sugar, and

c) providing a probe having an azide group and linking the probe to the alkyne functional group of the tagged glycoconjugate
through a triazole moiety by an azide-alkyne cycloaddition reaction to provide the tagged glycoconjugate linked to the probe
through the triazole moiety.

US Pat. No. 9,764,005

SUPPRESSION OF CANCER METASTASIS

Academia Sinica, Taipei ...

1. A method for suppressing human cancer metastasis comprising:
administering to a human having a metastatic cancer an effective amount of fibrillar human serum albumin and a pharmaceutically
acceptable carrier, wherein said administering reduces cancer metastasis in said human, and wherein said fibrillar human serum
albumin is produced by a method comprising:

dissolving human serum albumin in a detergent solution to provide dissolved human serum albumin;
applying said dissolved human serum albumin through a gel filtration column with a pore size that can separate proteins of
70 kDa molecular weight and above;

eluting said dissolved human serum albumin from said gel filtration column to provide an eluate; and
removing said detergent from said eluate.

US Pat. No. 9,759,726

REACTIVE LABELLING COMPOUNDS AND USES THEREOF

ACADEMIA SINICA, Taipei ...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,wherein:
B is boron;
each instance of G1, G2,G3, G5, G6, G7 and G8 is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkenyl, optionally substituted C1-6 alkynyl, optionally substituted aryl, optionally substituted acyl, —ORA, —CH2ORA, —OC(O)RA, —SRA, —N(RB)2, —N(RA)C(O)RA, —C(O)N(RB)2, —CN, —NO2, —C(O)RA, —C(O)ORA, —S(O)RA, —SO2RA, —SO3RA, —SO2N(RB)2, and —NHSO2RB;

each RA is independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, and optionally
substituted aryl;

each RB is independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl, and optionally
substituted aryl, or two RB taken together with the intervening nitrogen form a heterocycle;

each instance of G4a and G4b is fluoro, alkyl, alkoxy, aryloxy, or alkynyl;

wherein alkyl and alkoxy groups are unbranched, saturated, and have 1-4 carbon atoms; aryl groups and aryl groups of aryloxy
can be either carbocyclic aryl or heterocyclic aryl; carbocyclic aryl groups have a total of 6-20 carbon atoms, including
carbon atoms of substituents; heterocyclic aryl groups have a total of 5-20 carbon atoms, including carbon atoms of substituents;
carboalkoxy groups are alkyl esters of a carboxylic acid wherein alkyl groups are as defined above; each alkyl, aryl, alkoxy,
aryloxy, benzo, and carboalkoxy, independently, may be unsubstituted or substituted with one or more substituent; alkyl substituents
are halo, hydroxyl, amino, or aryl; aryl substituents are halo, hydroxyl, amino, alkyl, aryl, nitro, or carboxyl; and halo
substituents are fluoro or chloro; and

n is 0, 1, 2, 3, or 4.
US Pat. No. 9,796,778

ANTIBODIES AGAINST PATHOLOGICAL FORMS OF TDP-43 AND USES THEREOF

Academia Sinica, Taipei ...

1. An antibody or a fragment thereof that specifically binds to a transactivation responsive (TAR)-DNA-binding protein 43
kDa (TDP-43) oligomer comprising,
a heavy chain variable region comprising the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and
a light chain variable region comprising the amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7.
US Pat. No. 10,087,236

METHODS FOR MODIFYING HUMAN ANTIBODIES BY GLYCAN ENGINEERING

ACADEMIA SINICA, Taipei ...

1. A method for glycan engineering the Fc region of a human, chimeric or humanized IgG1 or IgG3 glycosylated antibody, the method comprising the steps of:(a) providing a human, chimeric or humanized IgG1 or IgG3 glycosylated antibody comprising an oligosaccharide attached at each Asn 297 in the Fc region;
(b) contacting the human, chimeric or humanized IgG1 or IgG3 glycosylated antibody with an endo-?-N-acetylglucosaminidase (endo-NAG) and alpha-fucosidase thereby digesting the oligosaccharide to a defucosylated N-Acetylglucosamine (GlcNAc) unit attached at each Asn 297 in the Fc region;
(c) contacting the defucosylated N-Acetylglucosamine (GlcNAc) unit with an endo-?-N-acetylglucosaminidase (endo-NAG) and a synthetic Gal2GlcNAc2Man3GlcNAc moiety joined to a leaving group, thereby coupling the terminal GlcNac of the synthetic Gal2GlcNAc2Man3GlcNAc moiety to the defucosylated N-Acetylglucosamine (GlcNAc) unit to form the structure Gal2GlcNAc2Man3GlcNAc2 attached at each Asn 297 of the Fc region of the human, chimeric or humanized IgG1 or IgG3 glycosylated antibody; and
(d) contacting the attached Gal2GlcNAc2Man3GlcNAc2 of step (c) with an alpha-2,6-sialyltransferase, CMP-Neu5Ac and a set of CMP-Neu5Ac regeneration enzymes comprising a pyrophosphatase and a cytidine monophosphate kinase, thereby adding a terminal Neu5Ac to each terminal galactose of the attached Gal2GlcNAc2Man3GlcNAc2, wherein the glycan engineered human, chimeric or humanized IgG1 or IgG3 antibody has a Neu5Ac2Gal2GlcNAc2Man3GlcNAc2 attached at each Asn 297 in the Fc region, and wherein the CMP-Neu5Ac is regenerated following the addition of the terminal Neu5Ac.

US Pat. No. 9,856,480

DNAZYME FOR SILENCING THE EXPRESSION OF EGFR

National Taiwan Universit...

1. An oligonucleotide or a modified sequence thereof, which specifically hybridizes to EGFR mutation mRNA so as to inhibit
the translation thereof in a cell, wherein the oligonucleotide comprises consecutive nucleotides having a sequence selected
from the group consisting of SEQ ID NOs:1 to 7.
US Pat. No. 9,750,844

COMPOSITION FOR USE IN WOUND HEALING IN BURNS

ACADEMIA SINICA, Taipei ...

1. A method for preventing and treating MRSA infection in a burn wound comprising:
applying to the burn wound in a subject in need thereof, a composition comprising Epinecidin-1 (Epi-1) incorporated into collagen
at a therapeutically effective amount to heal the burn wound, together with a pharmaceutically acceptable carrier, and

wherein Epi-1 consists of a peptide having the full length of the amino acid sequence of SEQ ID NO: 1.

US Pat. No. 10,130,714

ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY

ACADEMIA SINICA, Taipei ...

1. A dual anti-influenza and anti-inflammatory compound selected from the group consisting of:

US Pat. No. 10,086,054

RM2 ANTIGENS AND USE THEREOF

ACADEMIA SINICA, Taipei ...

1. A glycan conjugate having Formula (II-a) or Formula (II-b)
or a pharmaceutically acceptable salt thereof,
wherein
each instance of R1, R2, R4, R5, R6, R10, R11, R12, and R13 is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted carbohydrate, or an oxygen protecting group; or optionally R1 and R2 are taken with the intervening atoms to form an optionally substituted heterocyclic ring; or optionally R4 and R5 are taken with the intervening atoms to form an optionally substituted heterocyclic ring;
each instance of RN1, RN2, and RBN is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted acyl, or a nitrogen protecting group;
p is an integer of 1 to 10, inclusive;
each instance of L1 is independently a bond, —O—, —S—, —NRL1a—, —C(?O)—, —NRL1aC(?O)—, —NRL1aC(?O)O—, —C(?O)NRL1a—, —OC(?O)NRL1a—, —SC(?O)—, —C(?O)S—, —OC(?O)—, —C(?O)O—, —NRL1aC(?S)—, —C(?S)NRL1a—, trans-CRL1b?CRL1b—, cis-CRL1b?CRL1b—, —C?C—, —OC(RL1b)2—, —C(RL1b)2O—, —NRL1aC(RL1b)2—, —C(RL1b)2NRL1a—, —SC(RL1b)2—, —C(RL1b)2S—, —S(?O)2O—, —OS(?O)2—, —S(?O)2NRL1a—, —NRL1aS(?O)2—, or an optionally substituted C1-20 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain is replaced with —O—, —S—, —NRL1a—, —C(?O)—, NRL1aC(?O)—, —NRL1aC(?O)O—, —C(?O)NRL1a—, —OC(?O)NRL1a—, —SC(?O)—, —C(?O)S—, —OC(?O)—, —C(?O)O—, —NRL1aC(?S)—, —C(?S)NRL1a—, trans-CRL1b?CRL1b—, cis-CRL1b?CRL1b—, —C?C—, —S(?O)2O—, —OS(?O)2—, —S(?O)2NRL1a—, or —NRL1aS(?O)2—, wherein RL1a is hydrogen, optionally substituted C1-6 alkyl, or a nitrogen protecting group, or RL1a is joined with the adjacent carbon atom to form an optionally substituted heterocyclic ring, and wherein each occurrence of RL1b is independently selected from the group consisting of hydrogen, halogen, optionally substituted C1-10 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or RL1b is joined with the adjacent carbon or nitrogen or oxygen atom to form an optionally substituted carbocyclic or heterocyclic ring, or two RL1b groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;
each instance of L2 is independently a moiety derived from a crosslinking reagent capable of crosslinking the carrier and L1-H;
each instance of L3C is independently a crosslinking reagent or a moiety derived from a crosslinking reagent, wherein the crosslinking reagent is capable of crosslinking the carrier and L1-H;
each instance of RCN is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted acyl, or a nitrogen protecting group;
w is an integer of 1 to 100, inclusive;
y is 0 or an integer of 1 to 100, inclusive;
R5 is independently hydrogen, optionally substituted C1-6 alkyl, or an oxygen protecting group; or optionally R4 and R5 are taken with the intervening atoms to form an optionally substituted heterocyclic ring;
each instance of R3a, R3b, R3c, R3d, and R3g is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted carbohydrate, or an oxygen protecting group; or optionally R3c and R3b are taken with the intervening atoms to form an optionally substituted heterocyclic ring; or optionally R3b and R3d are taken with the intervening atoms to form an optionally substituted heterocyclic ring; or optionally R3f and R3g are taken with the intervening atoms to form an optionally substituted heterocyclic ring; and
each instance of R3f and R3e is independently hydrogen, optionally substituted C1-6 alkyl, or a nitrogen protecting group.

US Pat. No. 10,048,264

LUNG CANCER BIOMARKER

ACADEMIA SINICA, Taipei ...

1. A method for diagnosing and treating early stage lung cancers, comprising the following steps:(1) providing a sample from a patient, wherein said sample is a urine sample or a serum sample;
(2) detecting the amount of a lung cancer biomarker in said sample, wherein the lung cancer biomarker comprises a GM2-activator protein (GM2AP) protein represented by SEQ ID NO: 1 or SEQ ID NO: 2;
(3) assessing the amount of the lung cancer biomarker in said sample to diagnose whether the patient suffers from an early stage lung cancer or predict the lung cancer prognosis of the patient, wherein when the amount of the lung cancer biomarker in the urine sample or the serum sample of the patient is higher than a standard of a random selected subset of normal population, the patient is diagnosed as suffering from an early stage lung cancer, wherein the early stage is stage I or stage II; and
(4) administering a lung cancer treatment to the patient.
US Pat. No. 9,856,490

DROUGHT-TOLERANT TRANSGENIC PLANT

Academia Sinica, Taipei ...

1. A transgenic plant, comprising:
a recombinant DNA construct that contains a nucleic acid sequence operably linked to a promoter, the nucleic acid sequence
encoding an At14a-like 1 (AFL1) polypeptide having the sequence of SEQ ID NO: 2,
wherein the transgenic plant expresses a higher level of the AFL1 polypeptide and exhibits increased growth under a drought
condition as compared to a control plant lacking the recombinant DNA construct under the same condition.
US Pat. No. 9,795,666

HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR GENERATING VIRUS-LIKE PARTICLES

Academia Sinica, Taipei ...

1. A method of preparing an influenza virus-like particle (VLP), the method comprising:
obtaining a founder Vero cell stably transfected with a sequence encoding an influenza M1 and a sequence encoding an influenza
M2;

transfecting the Vero cells with one or more recombinant DNA molecules, which collectively encoding a first influenza hemagglutinin
(HA) and a first influenza neuraminidase (NA)

to obtain a first co-expression Vero cell that expresses the influenza M1, the influenza M2, the first influenza HA, and the
first influenza NA, wherein the expressions of the influenza M1, M2, HA and NA proteins in the first co-expression Vero cell
are controlled by one or more inducible expression systems;

culturing the first co-expression Vero cell under conditions to allow expressions of the influenza M1, the influenza M2, the
first influenza HA and the first influenza NA, and assembly of the VLP comprising the influenza M1, the influenza M2, the
first influenza HA and the first influenza NA, wherein the VLP lacks viral genetic materials; and

isolating the VLP from the culture supernatant of the first co-expression Vero cell.
US Pat. No. 9,982,041

COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS

ACADEMIA SINICA, (TW)

1. An isolated monoclonal antibody that specifically binds to Neu5Ac?2?3Gal?1?3GalNAc?1?3Gal?1?4Gal?1?4Glc?1, wherein the antibody comprises an H-CDR1, H-CDR2, and H-CDR3 wherein:(i) the H-CDR1 has the sequence of SEQ ID NO: 80;
(ii) the H-CDR2 has the sequence of SEQ ID NO: 82; and
(iii) the H-CDR3 has the sequence SEQ ID NO: 90, respectively;
and comprises an L-CDR1, L-CDR2 and L-CDR3 wherein:
(iv) the L-CDR1 has the sequence of SEQ ID NO: 99;
(v) the L-CDR2 has the sequence of SEQ ID NO: 101; and
(vi) the L-CDR3 has the sequence of SEQ ID NO: 109, respectively.

US Pat. No. 9,981,030

GLYCAN CONJUGATES AND USE THEREOF

Academia Sinica, Taipei ...

1. A homogeneous population of a glycan conjugate or a pharmaceutically acceptable salt thereof, comprising a carrier and a glycan wherein the glycan conjugate is of Formula (I-a)whereineach instance of R1, R2, R3, R4, R5, R6, and R7 is independently hydrogen, optionally substituted C1-6 alkyl, or an oxygen protecting group; or optionally R1 and R2 are taken with the intervening atoms to form a heterocyclic ring; or optionally R2 and R3 are taken with the intervening atoms to form a heterocyclic ring; or optionally R5 and R6 are taken with the intervening atoms to form a heterocyclic ring; or optionally R6 and R7 are taken with the intervening atoms to form a heterocyclic ring; or RN1 and RO1 are taken together with the intervening atoms to form a heterocyclic ring;
each instance of RN1, RN2, and RBN is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted acyl, or a nitrogen protecting group;
each instance of RO1 is independently hydrogen, optionally substituted C1-6 alkyl, or an oxygen protecting group;
each instance of L is independently a bond, —C(?O)—, —C(?O)NRLa—, —C(?O)S—, —C(?O)O—, —C(?S)NRLa—, trans-CRLb?CRLb—, cis-CRLb?CRLb—, —C?C—, —C(RLb)2O—, —C(RLb)2NRLa—, —C(RLb)2S—, —S(?O)2O—, —S(?O)2NRLa—, or an optionally substituted C1-30 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain is replaced with —O—, —S—, —NRLa—, —C(?O)—, —NRLaC(?O)—, —NRLaC(?O)O—, —C(?O)NRLa—, —OC(?O)NRLa—, —SC(?O)—, —C(?O)S—, —OC(?O)—, —C(?O)O—, —NRLaC(?S)—, —C(?S)NRLa—, trans-CRLb?CRLb—, cis-CRLb?CRLb—, —C?C—, —S(?O)2O—, —OS(?O)2—, —S(?O)2NRLa—, or —NRLaS(?O)2—, wherein each instance of RLa is hydrogen, optionally substituted C1-15 alkyl, or a nitrogen protecting group, or RLa is joined with the adjacent carbon atom to form an optionally substituted heterocyclic ring, and wherein each occurrence of RLb is independently selected from the group consisting of hydrogen, halogen, optionally substituted C1-15 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or RLb is joined with the adjacent carbon or nitrogen or oxygen atom to form an optionally substituted carbocyclic or heterocyclic ring, or two RLb groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;
each instance of L1 is independently a bond, —O—, —S—, —NRL1a—, —C(?O)—, —NRL1aC(?O)—, —NRL1aC(?O)O—, —C(?O)NRL1a—, —OC(?O)NRL1a—, —SC(?O)—, —C(?O)S—, —OC(?O)—, —C(?O)O—, —NRL1aC(?S)—, —C(?S)NRL1a—, trans-CRL1b?CRL1b—, cis-CRL1b?CRL1b—, —C?C—, —OC(RL1b)2—, —C(RL1b)2O—, —NRL1aC(RL1b)2—, —C(RL1b)2NRL1a—, —SC(RL1b)2—, —C(RL1b)2S—, —S(?O)2O—, —OS(?O)2—, —S(?O)2NRL1a—, —NRL1aS(?O)2—, or an optionally substituted C1-20 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain is replaced with —O—, —S—, —NRL1a—, —C(?O)—, —NRL1aC(?O)—, —NRL1aC(?O)O—, —C(?O)NRL1a—, —OC(?O)NRL1a—, —SC(?O)—, —C(?O)S—, —OC(?O)—, —C(?O)O—, —NRL1aC(?S)—, —C(?S)NRL1a—, trans-CRL1b?CRL1b—, cis-CRL1b?CRL1b—, —C?C?, —S(?O)2O—, —OS(?O)2—, —S(?O)2NRL1a—, or —NRL1aS(?O)2—, wherein each instance of RL1a is hydrogen, optionally substituted C1-6 alkyl, or a nitrogen protecting group, or RL1a is joined with the adjacent carbon atom to form an optionally substituted heterocyclic ring, and wherein each occurrence of RL1b is independently selected from the group consisting of hydrogen, halogen, optionally substituted C1-10 alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or RL1b is joined with the adjacent carbon or nitrogen or oxygen atom to form an optionally substituted carbocyclic or heterocyclic ring, or two RL1b groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;
each instance of L2 is independently a moiety derived from a crosslinking reagent capable of crosslinking the carrier and L1-H;
each instance of L3C is independently a crosslinking reagent capable of crosslinking the carrier and L1-H;
each instance of RCN is independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted acyl, or a nitrogen protecting group;
w is an integer of 1 to 100, inclusive; and
y is 0 or an integer of 1 to 100, inclusive;
p is an integer of 1 to 10, inclusive; and
n is an integer of 1 to 100, inclusive.

US Pat. No. 9,985,230

FLUORINE-MODIFICATION PROCESS AND APPLICATIONS THEREOF

ACADEMIA SINICA, Taipei ...

1. An electronic device, comprising electric-connected layers in order:a first electrode; a hole transport layer;
a fluorine-containing layer, which is deposited directly on said hole transport layer; an active layer, which is deposited directly on said fluorine-containing layer, an electron transport layer; and a second electrode; wherein said hole transport layer has a surface energy of 7-65 mJ/m2.
US Pat. No. 9,901,615

METHOD FOR TREATMENT OF GASTRIC ULCERS

ACADEMIA SINICA, Taipei ...

1. A method for treating an infection of Helicobacter pylori (H. pylori), comprising administering to a subject in need thereof a therapeutically effective amount of an antimicrobial peptide, wherein
said antimicrobial peptide is selected from the group consisting of epinecidin-1 (Epi-1), tilapia piscidin 3 (TP3), tilapia
piscidin 4 (TP4) and combination thereof.
US Pat. No. 10,118,969

COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY

ACADEMIA SINICA, (TW)

1. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to Neu5Ac?2?3Gal?1?3GalNAc?1?3Gal?1?4Gal?1?4Glc?1, wherein the antibody or antigen-binding fragment thereof comprises a glycan attached to Asn-297 of the Fc region, wherein the glycan has the formula:Sia2( ?2-6)Gal2GlcNAc2Man3GlcNAc2, as in the structure shown in FIG. 1, and wherein the antibody or antigen-binding fragment thereof comprises an H-CDR1, an H-CDR2, an H-CDR3, an L-CDR1, an L-CDR2, and an L-CDR3, wherein:(i) the H-CDR1 comprises the sequence of SEQ ID NO:152 (GFSLTSYG);
(ii) the H-CDR2 comprises the sequence of SEQ ID NO:153 (IWGEGST);
(iii) the H-CDR3 comprises the sequence of SEQ ID NO:154 (AMTGTAY);
(iv) the L-CDR1 comprises the sequence of SEQ ID NO:149 (SSVSY);
(v) the L-CDR2 comprises the sequence of SEQ ID NO:150 (DTS); and
(vi) the L-CDR3 comprises the sequence of SEQ ID NO:151(HQWSSSPHT).

US Pat. No. 9,971,229

SUPERCONTINUUM GENERATION APPARATUS AND METHOD

ACADEMIA SINICA, Taipei ...

1. A continuous spectrum generation apparatus, comprising:a laser light source configured to emit a laser beam;
a plurality of condensed state transparent plates, disposed in sequence on a transmitting path of the laser beam to successively and sequentially extend a spectral bandwidth of the laser beam, wherein one or more of temporal, spatial and spectral value of a pulse of the laser beam in a forward propagation direction z through a plate number n are determined as a function of z;
a pulse characterization apparatus configured to characterize the pulse of the laser beam; and
wherein a spacing between two of the plurality of plates is determined by where an intensity of the laser beam is ?/(2n0n2L), where ? is the central incident wavelength in vacuum, n0 is the linear refractive index, n2 is the third-order nonlinear coefficient, L is the thickness of the plates.
US Pat. No. 9,920,347

METHODS FOR PRODUCING VIRUS PARTICLES WITH SIMPLIFIED GLYCOSYLATION OF SURFACE PROTEINS

Academia Sinica, Taipei ...

1. A method for producing an immune composition comprising a monoglycosylated viral antigen, the method comprising:
a) producing a viral antigen in a suitable host with an effective amount of a glycosidase inhibitor, wherein the concentration
of the glycosidase inhibitor is sufficient to inhibit a glycosidase in the N-glycosylation pathway,

b) contacting the viral antigen recovered from step a) with an endoglycosidase to produce the viral antigen in monoglycosylated
form;

c) isolating the monoglycosylated viral antigen produced in step b); and
d) mixing the monoglycosylated viral antigen of (c) with a pharmaceutically acceptable carrier and/or an adjuvant to produce
an immunogenic composition.

US Pat. No. 10,214,765

CELL-PERMEABLE PROBES FOR IDENTIFICATION AND IMAGING OF SIALIDASES

Academia Sinica, Taipei ...

1. A compound of formula (I):
or a salt thereof,
wherein
F atom at the C3-position is axial or equatorial;
R1 is H or C1-6 alkyl;
R2 is OR2O, N3, N(R2N)2, or —NH(C?NH)NH2;
each instance of R2O is independently hydrogen, C1-6 alkyl, acyl, or a hydroxyl protecting group;
each instance of R2N is independently hydrogen, C1-6 alkyl, acyl, or an amine protecting group;
each instance of R3a and R3b is independently hydrogen, —C(?O)—R3r, or a hydroxyl protecting group;
each instance of R3r is C1-6 alkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl, or alkylheterocyclyl;
X is selected from the group consisting of —O—, —O(C?O)—, —NH—, —NH(C?O)—, —(C?O)NH—, —O(C?O)NH—, —O(C?S)NH—, —NH(C?O)NH—, and —NH(C?S)NH—;
R4 is H, C1-6 alkyl, or -L-Z;
Y is CF3, C1-6 alkyl or -L-Z;
each instance of L is independently selected from the group consisting of —(CH2)n—, —(CH2)nC?O—, —(CH2)nNH—, —(C?O)(CH2)n—, —(CH2)nNH(C?O)—, —(C?O)(CH2)nNH(C?O)—, —(CH2)nSCH2(C?O)—, and —(CH2CH2O)n—;
each instance of n is an integer from 1 to 8, inclusive;
each instance of Z is alkynyl, alkenyl, halogen, N(RN)2, ORO, SRS, or CO2RO;
each instance of RN is independently hydrogen, C1-6 alkyl, acyl, or an amine protecting group;
each instance of RO is independently hydrogen, C1-6 alkyl, acyl, or a hydroxyl protecting group;
each instance of RS is independently hydrogen, C1-6 alkyl, or a thiol protecting group;
provided that the compound is not of the formula

provided that when R4 is -L-Z, Y is C1-6 alkyl; and
provided that when Y is -L-Z, R4 is H or C1-6 alkyl.

US Pat. No. 10,119,972

REACTIVE LABELLING COMPOUNDS AND USES THEREOF

ACADEMIA SINICA, Taipei ...

1. A compound of formula (V) or (VI):
wherein L is selected from the group consisting of umbelliferyl, coumarin oxide, triflate, mesylate, tosylate, alkoxy, phenoxy, benzoate, pentafluorophenoxy, or 4-nitrophenoxy.

US Pat. No. 10,072,097

COMPOSITIONS AND METHODS FOR DETECTION OF PROTEIN S-NITROSYLATION AND OXIDATION

Academia Sinica, Taipei ...

1. A method for determining the presence or absence of protein S-nitrosylation or oxidation in a sample, the method comprising:blocking free thiols in the sample with thiol-reactive alkylating agents selected from the group consisting of iodoacetamide (IAM), N-(4-acetylphenyl)-2-iodoacetamide (APIAM) and N-(2,3-dimethylphenyl)-2-iodoacetamide (DPIAM);
contacting the sample with one or more reducing agents;
reacting with a 2-Iodo-N-phenylacetamide (IAN) to form N-phenylacetamidyl cysteine; and
detecting N-phenylacetamidyl cysteine by an anti-N-phenylacetamidyl cysteine (PAC) antibody, thereby determining the presence or absence of protein S-nitrosylation or oxidation.
US Pat. No. 10,036,033

METHOD OF INHIBITING SPROUTING IN PLANT TISSUES

Academia Sinica, Taipei ...

1. A method for inhibition of pre-harvest sprouting in monocot plant seeds, comprising(i) introducing a recombinant polynucleotide encoding a FCA protein into a monocot plant cell to obtain a transformed monocot plant cell, wherein the FCA protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2 and 3;
(ii) producing a transformed monocot plant from said transformed monocot plant cell, wherein the FCA protein is overexpressed in the transformed monocot plant; and
(iii) selecting a transformed monocot plant that produces plant seeds having a reduced level of pre-harvest sprouting as compared to a non-transgenic monocot plant, which is of the same species as the transformed monocot plant and not introduced with the recombinant polynucleotide encoding the FCA protein.
US Pat. No. 10,005,847

ANTI-HER2 GLYCOANTIBODIES AND USES THEREOF

ACADEMIA SINICA, Taipei ...

1. A composition of anti-HER2 glycoantibodies or antigen binding fragments comprising a homogeneous population of glycoengineered anti-HER2 IgG antibodies having the same N-glycan at the Asn-297 position in the Fc region of each anti-HER2 lgG antibody, wherein the N-glycan is selected from the group consisting ofSia2(?2-6)Gal2GlcNAc2Man3GlcNAc2, Sia2(?2-6)Gal2GlcNAc3Man3GlcNAc2, Sia2(?2-3)Gal2GlcNAc2Man3GlcNAc2, Sia2(?2-3)Gal2GlcNAc3Man3GlcNAc2, Sia2(?2-3/?2-6)Gal2GlcNAc2Man3GlcNAc2, Sia2(?2-6/?2-3)Gal2GlcNAc2Man3GlcNAc2, Sia2(?2-3/?2-6)Gal2GlcNAc3Man3GlcNAc2, Sia2(?2-6/?2-3)Gal2GlcNAc3Man3GlcNAc2, Sia(?2-6)Gal2GlcNAc2Man3GlcNAc2, Sia(?2-3)Gal2GlcNAc2Man3GlcNAc2, Sia(?2-6)Gal2GlcNAc3Man3GlcNAc2, Sia(?2-3)Gal2GlcNAc3Man3GlcNAc2, Sia(?2-6)GalGlcNAc2Man3GlcNAc2, Sia(?2-3)GalGlcNAc2Man3GlcNAc2, Sia(?2-6)GalGlcNAc3Man3GlcNAc2, Sia(?2-3)GalGlcNAc3Man3GlcNAc2, Gal2GlcNAc2Man3GlcNAc2, Gal2GlcNAc3Man3GlcNAc2, GalGlcNAc2Man3GlcNAc2, GalGlcNAc3Man3GlcNAc2, GlcNAc3Man3GlcNAc2, GlcNAc2, Man3GlcNAc2, GlcNAcMan3GlcNAc2 and Man3GlcNAc2.

US Pat. No. 9,957,481

SCAFFOLDS AND OTHER CELL-GROWTH STRUCTURES USING MICROFLUIDICS TO CULTURE BIOLOGICAL SAMPLES

Academia Sinica, Taipei ...

1. An apparatus for producing gas bubbles, comprising:an outer micropipette including an outer outlet having an outer outlet diameter, the outer micropipette configured to allow a liquid to flow through;
an inner micropipette located inside the outer micropipette to separate the interior within the outer micropipette into a gas flow region inside the inner micropipette and a liquid flow region between the inner micropipette and the outer micropipette, the inner micropipette including an inner outlet having an inner outlet diameter to allow a gas to flow through and to mix with the liquid before the liquid flows through the outer outlet to produce gas bubbles inside the liquid at the outer outlet, the outer micropipette and the inner micropipette being configured to make the gas bubbles as a single stream of gas bubbles uniform in size, one gas bubble at a time;
a first fluid inlet coupled to inner micropipette to receive the gas to pass through the inner micropipette;
a second fluid inlet coupled to the outer micropipette to receive the liquid to pass through the region inside the outer micropipette and between the outer micropipette and the inner micropipette,
wherein a surface of the inner outlet and a surface of the outer inlet are separated by a distance between and including 350 ?m and 450 ?m, the diameter of the inner outlet is between 25 ?m and 35 ?m, and the diameter of the outer outlet is between and including 60 ?m and 75 ?m; and
a formation device for collecting the produced gas bubbles to form a matrix structure, wherein the formation device includes
a reservoir that holds gas bubbles;
an input channel that is connected to the reservoir to direct the gas bubbles output by the outer micropipette into the reservoir;
an output channel that is connected to the reservoir to direct excessive gas bubbles out of the reservoir; and
a reservoir cover removably engaged to cover a top opening of the reservoir to form an enclosure for containing the gas bubbles in a shape defined by the reservoir and the reservoir cover to be crosslinked to form a matrix structure.

US Pat. No. 9,958,396

SENSING DEVICE, AND SENSING SYSTEM AND SENSING METHOD USING THE SAME

Academia Sinica, Taipei ...

1. A sensing device applied to an analyte molecule of a liquid sample and a buffer flow, comprising:at least one first inlet, for inputting the liquid sample;
at least one second inlet, for inputting the buffer flow;
a micro-flow channel, communicating with the first inlet and the second inlet; and
at least one immobilization element for immobilizing a sensing molecule for the analyte molecule and the buffer flow in the micro-flow channel,
wherein the micro-flow channel has two ends which are respectively connected to the first inlet and the second inlet, and the micro-flow channel is between the first inlet and the second inlet,
wherein the sensing molecule is capable of generating an association reaction with the analyte molecule of the liquid sample, and generating a dissociation reaction with the analyte molecule and the buffer flow in reverse direction,
wherein the sensing molecule and the analyte molecule of the liquid sample are configured to generate the association reaction after the liquid sample flows into the micro-flow channel for association reaction observation,
and then the sensing molecule and the analyte molecule are configured to generate the dissociation reaction after the buffer flow flows reversely into the micro-flow channel for dissociation reaction observation.

US Pat. No. 10,016,748

IRON-SULFUR COMPLEX AND METHOD FOR PRODUCING HYDROGEN USING THE SAME AS CATALYST

ACADEMIA SINICA, Taipei ...

1. An iron-sulfur complex, comprising: a structure of formula (I)
wherein
Z is a charge selected from an integer of ?3 to +2;
L1, L2, L3, L5, or L6, X1, or X2 is a substituted or an unsubstituted functional group selected from the group consisting of: alkyl, alkenyl, alkynyl, phenyl, benzyl, hydroxyl, carbonyl, aldehyde, haloformyl, carbonate ester, carboxylate, carboxyl, ester, methoxy, hydroperoxy, peroxy, ether, hemiacetal, hemiketal, acetal, ketal, orthoester, orthocarbonate ester, carboxamide, primary amine, secondary amine, tertiary amine, primary ketimine, secondary ketimine, primary aldimine, secondary aldimine, imide, azide, azo, cyanate, isocyanate, nitrate, nitrile, isonitrile, nitrosooxy, nitro, nitroso, pyridyl, sulfhydryl, sulfide, disulfide, sulfinyl, sulfonyl, sulfino, sulfo, thiocyanate, isothiocyanate, carbonothioyl, phosphino, phosphono, phosphate, borono, boronate, borino, borinate and halogen;
X1 and X2 are substituents within one bridging group;
L4 is a bridging ligand selected from the group consisting of hydroxyl, cyanide, primary amide, secondary amide, sulfide, disulfide, sulfinyl, ethylthio (SEt), phenylthio (SPh), t-butylthio (StBu), thiolate, phosphide, halide, oxide, nitride, borylene, boryl, boride and hydride;
X3 is a vacant site or a substituted or an unsubstituted functional group selected from the group consisting of: alkyl, alkenyl, alkynyl, phenyl, benzyl, hydroxyl, hydrogen, carbonyl, aldehyde, haloformyl, carbonate ester, carboxyl ate, carboxyl, ester, methoxy, hydroperoxy, peroxy, ether, hemiacetal, hemiketal, acetal, ketal, orthoester, orthocarbonate ester, carboxamide, primary amine, secondary amine, tertiary amine, primary ketimine, secondary ketimine, primary aldimine, secondary aldimine, imide, azide, azo, cyanate, isocyanate, nitrate, nitrile, isonitrile, nitrosooxy, nitro, nitroso, pyridyl, sulfhydryl, sulfide, disulfide, sulfinyl, sulfonyl, sulfino, sulfo, thiocyanate, isothiocyanate, carbonothioyl, phosphino, phosphono, phosphate, borono, boronate, borino, borinate and halogen.

US Pat. No. 10,005,746

MOLECULAR CATALYSTS CAPABLE OF CATALYZING OXIDATION OF HYDROCARBONS AND METHOD FOR OXIDIZING HYDROCARBONS

ACADEMIA SINICA, Taipei ...

1. A catalytic process for oxidation of a hydrocarbon to generate an oxidation product, said process comprising the steps of:contacting said hydrocarbon with a copper catalyst in the presence of an oxidizing agent; thereby generating said oxidation product; and
regenerating said copper catalyst;
wherein said copper catalyst comprises a tricopper complex comprising three Cu ions and a ligand (L) having the formula (FX8):

US Pat. No. 10,000,747

ENDOGLYCOSIDASE MUTANTS FOR GLYCOPROTEIN REMODELING AND METHODS OF USING IT

Academia Sinica, Taipei ...

1. A mutant of endoglycosidase S2 (EndoS2), comprising: one or more mutations in the sequence of a wild-type EndoS2 as set forth in SEQ ID NO: 1, wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-178, residue 182, residues 187-189, residues 221-231, and residues 232-237, wherein the mutant of EndoS2 has a hydrolyzing activity lower than that of the wild-type EndoS2 and has a transglycosylation activity higher than that of the wild-type EndoS2, and wherein the mutation at residue 182 is D182Q.
US Pat. No. 9,975,965

COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS

ACADEMIA SINICA, (TW)

1. An isolated monoclonal antibody or a binding fragment thereof, that specifically binds to Neu5Ac?2?3Gal?1?3GalNAc?1?3Gal?1?4Gal?1?4Glc?1, wherein the antibody or the binding fragment thereof comprises a VH sequence having SEQ ID NO: 202, SEQ ID NO. 212, or SEQ ID NO: 222 and a VL sequence having SEQ ID NO: 203, SEQ ID NO. 213 or SEQ ID NO: 223.

US Pat. No. 9,884,306

CONVECTION-FREE FLOW-TYPE REACTOR AND FLOW-TYPE SYNTHESIS METHOD

ACADEMIA SINICA, Taipei ...

10. A convection-free flow synthesis method, comprising:
providing a convection-free flow reactor comprising:
a reactor body comprising:
a reaction chamber to house a fluid;
an inlet in communication with the reaction chamber to allow input of a reactant fluid, wherein the reactant fluid consists
of a precursor solution of nanoparticles;

an outlet in communication with the reaction chamber to allow output of a product fluid;
a first component having a reactant loading space; and
a second component having a window corresponding to the reactant loading space, wherein an energy beam transmissible material
is disposed between the first and second components; and

an energy beam source device providing an energy beam to irradiate the reactant fluid in the reaction chamber, wherein the
window of the second component of the reactor body has an area smaller than a cross-sectional area of the energy beam;

inputting the reactant fluid into the reaction chamber through the inlet; and
irradiating the reactant fluid in the reaction chamber through the energy beam transmissible material by the energy beam to
form the product fluid in a convection-free manner, wherein the product fluid is output through the outlet, and wherein the
energy beam comprises X-ray.

US Pat. No. 9,879,042

HUMAN INKT CELL ACTIVATION USING GLYCOLIPIDS

ACADEMIA SINICA, Taipei ...

10. A compound selected from one of the following:

US Pat. No. 9,874,562

ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES

ACADEMIA SINICA, Taipei ...

1. A method for detecting the presence of oseltamivir-resistant influenza virus using a synthetic binding molecule, the method
comprising the steps of:
(a) providing a sample suspected of comprising an oseltamivir-resistant influenza-virus or virus particle;
(b) contacting the sample with a synthetic binding molecule comprising a fluorescent reporting element in the presence and
absence of oseltamivir carboxylate (OC);

(c) measuring the fluorescence of the reporting element of the synthetic binding molecule in the presence and absence of said
oseltamivir carboxylate (OC); and

(d) measuring a difference in fluorescence the reporting element of the synthetic binding molecule bound to the influenza
virus, or viral particle, in the presence and absence of oseltamivir,

wherein a lack of fluorescence by the reporting element of the synthetic binding molecule in the presence of oseltamivir as
compared to the fluorescence when contacted with a oseltamivir-sensitive influenza virus control, detects the presence of
an oseltamivir-resistant influenza virus in the sample,

wherein the synthetic binding molecule comprising a fluorescent reporting element is selected from the group consisting of:
BM 2: Zanamivir-(Triazole Linker)-Fluorescein

BM 4: Zanamivir-(Ethylene Glycol Linker)-Fluorescein

BM 6: (Tamiphosphor Guanidine)-(Ethylene Glycol Linker)-Fluorescein

BM 8: PhosphaZanamivir-(Ethylene Glycol Linker)-Fluorescein
and
BM 10: (PhosphaZanamivir Monoester)-(Ethylene Glycol Linker)-Fluorescein

wherein x=1 to 4.

US Pat. No. 10,112,198

COLLECTOR ARCHITECTURE LAYOUT DESIGN

Academia Sinica, Taipei ...

1. A microfluidic channel comprising:a plurality of microstructures within the channel; wherein the plurality of microstructures is arranged in a plurality of columns substantially parallel to one another, wherein the plurality of columns comprise at least four columns comprising a first column adjacent to a second column, the second column adjacent to a third column, and the third column adjacent to a fourth column; wherein the number of microstructures in the first column is greater than the number of microstructures in the second column or the third column; and wherein the number of microstructures in the fourth column is greater than the number of microstructures in the second column or the third column; and
a plurality of vortex regions at which one or more vortexes are generated in response to fluid flow, wherein each vortex region of the plurality is substantially free of the plurality of microstructures and comprises at least a cylindrical volume having (1) a height of the channel and (2) a base having a diameter at least 20% a width of the channel, wherein the plurality of vortex regions of the plurality are separated from each other by at least one microstructure along a length of the channel; and
wherein said vortex regions are configured to increase the mixing of particles of interest and thereby to increase the likelihood of binding particles of interest to a microstructure.
US Pat. No. 10,034,848

INCREASE OF PROTEIN SYNTHESIS AMELIORATES SYNAPTOPATHY-RELATED NEUROLOGICAL DISORDERS

Academia Sinica, Taipei ...

1. A method of increasing dendritic spine formation or increasing dendritic spine density in a subject, consisting of administering to the subject 0.01 to 1 g/Kg body weight per day of a leucine or a pharmaceutically acceptable salt thereof as the sole active ingredient, whereinthe subject suffers from a dendritic spine defect caused by impairment in neurofibromin (NF1 protein), and
the administration of 0.01 to 1 g/Kg body weight per day of the leucine or the pharmaceutically acceptable salt thereof increases dendritic spine formation or increases dendritic spine density in the subject.
US Pat. No. 10,023,892

COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY

ACADEMIA SINICA, Taipei ...

1. A composition comprising an essentially homogeneous population of glycoengineered monoclonal IgG1 or IgG3 glycoantibodies or antigen binding fragments thereof, wherein the glycoengineered monoclonal IgG1 or IgG3 glycoantibodies or antigen binding fragments thereof have a Sia2(?2-6)Gal2GlcNAc2Man3GlcNAc2 at each Asn-297 position in the Fc region, and wherein the glycoengineered monoclonal IgG1 or IgG3 glycoantibodies or antigen binding fragments comprising the essentially homogeneous population have less than about 2% of precursor N-glycan.
US Pat. No. 9,925,235

TILAPIA PISCIDINS FOR USE IN ENHANCEMENT OF WOUND HEALING

ACADEMIA SINICA, Taipei ...

1. A method for treating methicillin-resistant Staphylococcus aureus (MRSA) infection in a wound, comprising administering to a subject in need thereof a therapeutically effective amount of tilapia piscidin 3 (TP3) or tilapia piscidin 4 (TP4).

US Pat. No. 9,915,614

MICROFLUIDIC SYSTEMS AND DEVICES FOR MOLECULAR CAPTURE, MANIPULATION, AND ANALYSIS

ACADEMIA SINICA, Taipei ...

1. A device to capture and characterize particles in a fluid by combining sensing via electrical tunneling and coherent optical
Raman sensing, comprising:
a substrate that is electrically insulating;
a channel formed of an electrically insulative material on the substrate and structured to carry an electrically conducting
fluid containing particles;

a first electrode and a second electrode formed of an electrically conductive material and located in the channel to form
an opening with a size in the nanometer range, each of the first and second electrodes structured to include a tip having
an angle from 20 degrees to 120 degrees and including an electrically insulating layer over the electrode surface including
at the opening between the electrodes;

a first circuit electrically coupled to the first and second electrodes to apply a non-uniform AC electric field and a DC
bias signal across the first and second electrodes, wherein the applied non-uniform AC electric field produces a positive
dielectrophoretic force (FPDEP) in a direction towards the opening to capture a low quantity of the particles including 1,000 particles or fewer in a trapping
region including the opening and in a region adjacent to the opening;

a second circuit coupled to the first and second electrodes to detect changes in a DC current produced by electrical tunneling
through the opening and the electrically insulating layers over the electrode surfaces of the first and second electrodes
based on operation of the applied DC bias signal and caused by at least some of the captured particles in the trapping region
due to operation of the first circuit; and

an optical device including a laser to direct a coherent light beam on the opening and including a detector to detect inelastic
scattering of the light beam by at least some of the captured particles in the trapping region due to operation of the first
circuit to determine their Raman spectra.

US Pat. No. 9,914,956

CELL-PERMEABLE PROBES FOR IDENTIFICATION AND IMAGING OF SIALIDASES

Academia Sinica, Taipei ...

1. A sialidase protein adduct having the formula:

wherein
R2 is OR2O;

each instance of R2O is independently hydrogen, C1-6 alkyl, or acyl;

each instance of R3a and R3b is independently hydrogen, or —C(?O)—R3r, or when taken together R3a and R3b form a C1-6 alkyl substituted five-membered heterocyclyl ring;

each instance of R3r is C1-6 alkyl;

X is selected from the group consisting of —O—, —O(C?O)—, and —O(C?O)NH—,
R4 is H, C1-6 alkyl, or -L-Z;

Y is C1-6 alkyl or -L-Z;

each instance of L is —(CH2)n—,

each instance of n is an integer from 1 to 8, inclusive;
each instance of Z is an alkynyl;
wherein when R4 is H or C1-6 alkyl, then Y is -L-Z;

wherein when Y is C1-6 alkyl, R4 is -L-Z;

with the proviso that only one of R4 or Y is -L-Z; and

with the proviso that the C-1 carboxyl is covalently conjugated to a tyrosine residue at the tyrosinyl phenolic hydroxyl oxygen,
of a sialidase protein.

US Pat. No. 9,906,920

BUILDING DESIGN INFORMATION BASED INDOOR POSITIONING SYSTEM

ACADEMIA SINICA, Taipei ...

1. An indoor positioning system, comprising a plurality of beacons to be installed at selected locations in a building, a
server computer to provide an indoor position information database, and at least one IPS installer to provide particular indoor
position information files to corresponding beacons and assists the installations of the beacons at their selected locations;
wherein the beacon comprises:
an indoor position information storage unit to store an indoor position information file containing an indoor position message,
a wireless broadcast unit to broadcast the indoor position message and
a power supply to supply power to the indoor position information storage unit and the wireless broadcast unit;
wherein the server computer provides an indoor position information database comprising a plurality of indoor position information
files;

wherein the IPS installer is in connection with the server computer and is configured to obtain an indoor position information
file of each beacon from the server computer and install the obtained indoor position information file in a designated beacon;
and

wherein the indoor position information storage unit provides a configuration interface, to accept configuration instructions
from the IPS installer, whereby an indoor position information file may be installed into or modified/replaced in the indoor
position information storage unit.

US Pat. No. 9,891,227

ULTRASENSITIVE DETECTION OF A BIOLOGICAL TARGET BY APTAMER-CONJUGATED GOLD NANOPARTICLES

ACADEMIA SINICA, Taipei ...

1. An ultrasensitive method of assaying a biological target, comprising:
(a) providing a sample containing the biological target;
(b) (i) providing a plurality of biotin-labeled first aptamers, the biotin-labeled first aptamers being conjugated to a gold
nanoparticle; and

(ii) providing a plurality of second aptamers, the second aptamers being conjugated to a magnetic bead, wherein the biotin-labeled
first aptamers and the second aptamers exhibit specific binding affinities to the biological target;

(c) incubating the sample with the biotin-labeled first aptamers and the second aptamers to obtain biological target-bound
aptamers;

(d) separating the biological target-bound aptamers from unbound aptamers;
(e) eluting the biotin-labeled first aptamers from the gold nanoparticle in the biological target-bound aptamers to obtain
eluted biotin-labeled first aptamers unconjugated to the gold nanoparticle;

(f) incubating the eluted biotin-labeled first aptamers unconjugated to the gold nanoparticle with a plurality of streptavidin-magnetic
beads and a plurality of reporter gold nanoparticles to obtain a complex comprising:

(i) the streptavidin-magnetic bead;
(ii) the biotin-labeled first aptamers, attached to the streptavidin-magnetic bead; and
(iii) the reporter gold nanoparticle, each of which being attached to one of the biotin-labeled first aptamers and captured
by the streptavidin-magnetic bead through the biotin-labeled first aptamers;

(g) eluting the reporter GNPs captured by the streptavidin-magnetic bead from the complex; and
(h) detecting the biological target by measuring and analyzing a light-scattering signal of the eluted reporter gold nanoparticles.

US Pat. No. 9,799,479

METHOD, SYSTEM, AND LIGHT SOURCE FOR PENETRATING RADIATION IMAGING

ACADEMIA SINICA, (TW)

1. An X-ray source for X-ray imaging, comprising:
an electron gun configured to generate an electron beam;
a plate; and
a plurality of metal micro-targets distributed over a surface of the plate to form an array of metal micro-targets, and each
of the plurality of the metal micro-targets being formed in the shape of a column extending from the surface of the plate;

wherein the electron beam hits a portion or all of the plurality of metal micro-targets on the plate to generate X-rays.

US Pat. No. 10,238,631

SESQUITERPENE DERIVATIVES AND THEIR USE IN INFLAMMATION OR CANCER TREATMENT

Academia Sinica, Taipei ...

1. A compound of Formula (I)
or a pharmaceutically acceptable salt thereof,
wherein R1 is selected from the group consisting of hydrogen, -carbonyl(C1-C8)alkyl(C1-C8)alkenyl, -carbonyl(C1-C8)alkyl(C1-C8)alkenyl(C1-C8)alkyl, -carbonyl(C1-C8)alkenyl(C6-C20)aryl, -carbonyl(C1-C8)alkenyl(C1-C8)alkoxy(C6-C20)aryl, -carbonyl(C1-C8)alkenyl, -carbonyl(C1-C8)haloalkyl, -carbonyl(C1-C8)alkyl, -carbonyl(C1-C8)alkylOCO(C1-C8)alkyl, -carbonyl(C1-C8)alkenyl(C1-C8)alkyl(C1-C8)alkenyl, -carbonyl(C1-C8)alkanol(C1-C8)alkyl, -carbonyl(C1-C8)alkenyl(C1-C8)alkyl(C6-C20)aryl, -carbonyl(C1-C8)alkenyl(C6-C20)haloaryl, -carbonyl(C1-C8)alkenyl(C3-C8)heteroaryl, -carbonyl(C6-C20)aryl, -carbonyl(C1-C8)alkoxy(C6-C20)aryl, -carbonyl(C1-C8)alkyl(C6-C20)aryl, -carbonylhalo(C6-C20)aryl, -carbonyl(C3-C8)cycloalkyl, -carbonyl(C1-C8)alkenyl(C1-C8)haloalkyl(C6-C20)aryl, —CO-(E)C(CH3)?CHCH2CH3, —CO-(E)CH?CHCH2CH3, —CO—C(CH2CH3)?CH2, —CO-(E)CH?C(CH3)CH(CH3)2, —CO-2-thiofuranyl, —CO-benzofuran-2-yl, —CO-benzothiofuran-2-yl, —CO-(4-methylphenyl), —CO—CH2-(4-methoxyphenyl), —CO—CH2-(6-methoxynaphthalene-1-yl), —CO—CH2-(6-methoxynaphthalene-2-yl), —CO—CH2-(quinolin-8-yl), —CO—CH2-(benzothiofuran-3-yl), —CO—CH2-(benzofuran-3-yl), —CO—CH2-(napthalene-1-yl), —CO—CH(S—CH3)(6-methoxylnaphthalene-2-yl), and -carbonyl(C1-C8)alkyl(C1-C8)alkoxy(C6-C20)aryl.
US Pat. No. 10,232,013

USE OF AN ANTIMICROBIAL PEPTIDE TP4 IN TREATING A CANCER

Academia Sinica, Taipei ...

1. A method for treating a breast cancer or a triple negative breast cancer (TNBC) in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of tilapia piscidin 4 (TP4), together with a pharmaceutically acceptable carrier.
US Pat. No. 10,184,128

METHOD FOR HIGH EFFICIENCY PROTEIN DELIVERY INTO PLASTIDS

ACADEMIA SINICA, Taipei ...

1. A recombinant DNA molecule encoding a fusion protein, wherein said recombinant DNA molecule comprises a first DNA sequence encoding a transit peptide operably linked to a second DNA sequence encoding a passenger protein, wherein the transit peptide consists of the first 40 amino acids of SEQ ID NO: 18.

US Pat. No. 10,111,951

HUMAN INKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS

ACADEMIA SINICA, Taipei ...

1. A method for augmenting an immunogenicity of an antigen in a subject in need thereof, comprising co-administering said antigen with an adjuvant composition comprising a compound having a structure of Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
R1 is —OH or halogen;
R2 is —OH or halogen;
R3 is hydrogen;
R4 is selected from the group consisting of optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted alkoxy, an optionally substituted amino group, and optionally substituted acyl;
R5 is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted alkoxy, an optionally substituted amino group, and optionally substituted acyl;
n is an integer of 1 to 15, inclusive; and
m is an integer of 1 to 20, inclusive.
US Pat. No. 10,087,450

ENGINEERED YEAST FOR PRODUCTION OF ENZYMES

Academia Sinica, Taipei ...

1. An engineered Kluyveromyces marxianus cell, the cell comprising in its genome:(i) two different nucleic acid molecules that each contain a promoter operably linked to a gene encoding a functional enzyme, and
(ii) a selection nucleic acid molecule that contains a promoter operably linked to a gene encoding a selectable marker,wherein all of the nucleic acids molecules of (i) and (ii) are in tandem, the engineered cell expresses all of the proteins encoded by the genes of (i) and (ii), and each functional enzyme is a cellulolytic enzyme.

US Pat. No. 9,890,111

CRYSTAL STRUCTURE OF BIFUNCTIONAL TRANSGLYCOSYLASE PBP1B FROM E. COLI AND INHIBITORS THEREOF

Academia Sinica, Taipei ...

1. An anti-bacterial compound having the formula:

wherein R1?Br, Cl, I, H or OH;

R2?H, OH or Cl;

R3?Br, Cl, I, H, or


R4=


R5?Cl,


R6?H, CH3, OH, OCH3, Cl, NO2, or


R7?H, Cl,


US Pat. No. 10,248,324

OBLIVIOUS PARALLEL RANDOM ACCESS MACHINE SYSTEM AND METHODS

Cornell University, Itha...

1. A secure computer method enabling two or more processors to simultaneously access a shared external memory, the method comprising the steps of:selecting a processor from two or more processors to obtain a selected processor and one or more unselected processors, said selecting step occurring when each of the two or more processors require simultaneous access to a data item;
aggregating by the selected processor instructions of each of the two or more processors to obtain aggregated instructions;
accessing a memory by the selected processor to obtain a read value of the data item, wherein the data item is stored in a node of a binary tree structure, the node comprising a collection of data items;
recording by the selected processor the read value of the data item;
removing by the selected processor the data item from both the collection of the note and all other collections of other nodes along a path of the node;
communicating by the selected processor to the one or more unselected processors the read value of the data item;
routing the data item between the two or more processors until an ith processor holds the data item to be inserted to an ith node such that the data item is assigned a new position in the binary tree structure to obtain a new node comprising a corresponding path; and
inserting by the selected processor the data item at the new node or along the corresponding path without revealing any information about the new node and the corresponding path to obtain a write value of the data item.
US Pat. No. 10,214,564

ANTIMICROBIAL PEPTIDES DERIVED FROM HEPATITIS B VIRUS CORE PROTEIN ARGININE-RICH DOMAIN

Academia Sinica, Taipei ...

1. A pharmaceutical composition comprising:(a) an effective amount of an isolated peptide, wherein the peptide consists of a protecting group and the amino acid sequence of SEQ ID NO:1, and exhibits an anti-bacterial or anti-fungal activity; and
(b) a pharmaceutically acceptable carrier.
US Pat. No. 10,213,967

FABRICATING DEVICE OF THREE-DIMENSIONAL SCAFFOLD AND FABRICATING METHOD THEREOF

Academia Sinica, Taipei ...

1. A method of fabricating a 3-D scaffold, comprising steps of:(A) supplying a gel solution and an airflow into a bubble generator to form a plurality of bubbles;
(B) supplying the bubbles into a bubble mixing channel through which the bubbles flow to a bubble collector;
(C) adding a coagulating solution into the bubble mixing channel before the bubbles are collected to result in a gel coagulation effect in the bubble mixing channel;
(D) collecting the bubbles in the bubble collector before the gel coagulation effect is finished; wherein the gel coagulation effect is a reaction that a foam containing the gel solution is coagulated into a solid-state structure; and
(E) communicating with at least a part of the bubbles to form a 3-D scaffold,
wherein the bubble mixing channel is connected to a coagulating solution channel through which the coagulating solution is added, and the bubble mixing channel includes at least a bent portion and a first outlet, the bent portion is disposed between the first outlet and an intersection of the bubble mixing channel and the coagulating solution channel, the bubbles start to contact the coagulating solution at the intersection of the bubble mixing channel and the coagulating solution channel and the gel coagulation effect is thus started; wherein the bubbles are changed in shape because of flowing through the bent portion.

US Pat. No. 10,172,919

METHOD FOR TREATING INFLUENZA A VIRUS INFECTION

ACADEMIA SINICA, Nankang...

1. A method of suppressing influenza A virus-induced inflammatory response in a subject comprising administering to the subject a therapeutically effective amount of a fusion protein, which comprises a first peptide consisting of SEQ ID NO: 4, and a human IgG1 Fc region coupling to the first peptide.
US Pat. No. 10,150,818

COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS

Academia Sinica, Taipei ...

1. An isolated humanized monoclonal antibody that specifically binds to Neu5Ac?2?3Gal?1?3GalNAc?1?3 Gal?1?4Gal?1?4Glc?1, wherein the antibody comprises an H-CDR1, an H-CDR2, an H-CDR3, an L-CDR1, an L-CDR2, and an L-CDR3 wherein(i) the H-CDR1 comprises the sequence of SEQ ID NO:152 (GFSLTSYG);
(ii) the H-CDR2 comprises the sequence of SEQ ID NO: 153 (IWGEGST);
(iii) the H-CDR3 comprises the sequence of SEQ ID NO:154 (AMTGTAY);
(iv) the L-CDR1 comprises the sequence of SEQ ID NO: 149 (SSVSY);
(v) the L-CDR2 comprises the sequence of SEQ ID NO:150 (DTS); and
(vi) the L-CDR3 comprises the sequence of SEQ ID NO: 151(HQWSSSPHT).

US Pat. No. 10,117,890

METHODS AND COMPOSITIONS FOR TREATING PAIN

Academia Sinica, Taipei ...

1. A method for treating fibromyalgia, comprising administering to a subject in need thereof an effective amount of an adenosine analog, wherein the adenosine analog is a compound of Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein R3 is hydroxymethyl (HOCH2);
n is 1, 2 or 3; and
R4 is an unsubstituted phenyl or a phenyl substituted with a hydroxyl, a halogen group, or both.

US Pat. No. 10,301,348

COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN

ACADEMIA SINICA, Taipei ...

1. A compound of formula (I) or (IA):or a pharmaceutically acceptable salt thereof, wherein X is halogen.

US Pat. No. 10,273,411

BATCH-PROCESS SUPERTORREFACTION SYSTEM AND METHOD

ACADEMIA SINICA, Taipei ...

1. A supertorrefaction system comprising:at least one supertorrefying unit defining a receiving space for receiving biomass;
a liquid tank in fluid communication with the at least one supertorrefying unit and containing a first heat transfer liquid;
a wash tank in fluid communication with the at least one supertorrefying unit and containing a second heat transfer liquid;
a first filtration apparatus provided between the at least one supertorrefying unit and the liquid tank;
a second filtration apparatus provided between the at least one supertorrefying unit and the wash tank; and
an oxidizer comprising carbonate salt and nitrate salt as catalyst;
wherein the at least one supertorrefying unit receives the first heat transfer liquid from the liquid tank to supertorrefy and convert the biomass into charcoal, and receives the second heat transfer liquid from the wash tank to rinse and cool the charcoal without moving the biomass and the charcoal during supertorrefaction and cooling processes;
wherein the wash tank includes a plurality of basins containing the second heat transfer liquid having different temperatures and salinity, and
wherein the first heat transfer liquid is molten salt.
US Pat. No. 10,266,838

METHODS FOR ENHANCING ROOT GROWTH OF PLANTS

Academia Sinica, Taipei ...

1. A method for enhancing root growth of a plant, comprising(i) introducing a polynucleotide encoding a group 3 late embryogenesis abundant (LEA3) protein into plant cells to obtain transformed plant cells, wherein the polynucleotide is operably linked to an expression control sequence, and wherein the LEA3 protein comprises the amino acid sequence of SEQ ID NO: 4,
(ii) regenerating transformed plants from said transformed plant cells; and
(iii) selecting from said transformed plants a transformed plant exhibiting improved root growth as compared to a non-transformed control plant.
US Pat. No. 10,195,231

MODIFIED NATURAL KILLER CELLS, COMPOSITIONS AND USES THEREOF

Academia Sinica, Taipei ...

1. A method of obtaining a human NK cell possessing both NK cell function and dendritic cell function, comprising the steps of:(a) obtaining a human peripheral blood mononuclear cell;
(b) culturing the human peripheral blood mononuclear cell with IL-15, IL-12, and IFN-? to obtain a cultured cell population; and
(c) isolating the human NK cell possessing both NK cell function and dendritic cell function from the cultured cell population with the cell marker CD3?CD56+CD16+NKG2D+CD86+HLA?DR+CD83+.
US Pat. No. 10,307,470

ANTIBODY-MEDIATED ANTI-TUMOR ACTIVITY INDUCED BY REISHI MUSHROOM POLYSACCHARIDES

ACADEMIA SINICA, Taipei ...

1. An immunogenic composition, consisting of:a fucose-enriched Reishi polysaccharide fraction (FMS) of average molecular weight 35 kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and wherein the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-?-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain; and
an adjuvant, wherein the adjuvant is a glycolipid.
US Pat. No. 10,307,475

METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS

Academia Sinica, Taipei ...

1. A method of manufacturing an immunogenic composition the method comprising:(i) providing a viral glycoprotein, or immunologically active fragment thereof, which comprises a glycan bound to a glycosylation site of the viral glycoprotein, or the immunologically active fragment thereof;
(ii) removing a portion of the glycan to form a truncated glycan, which consists of one, two, or three sugar residues, to produce the partially glycosylated viral glycoprotein comprising the truncated glycan; and
(iii) formulating the partially glycosylated viral glycoprotein or immunologically active fragment thereof produced in step (ii) into an immunogenic composition, which further comprises an adjuvant.

US Pat. No. 10,308,596

HDAC8 INHIBITORS FOR TREATING CANCER

CITY OF HOPE, Duarte, CA...

1. A compound having the formula (I):wherein:R1 is substituted or unsubstituted 2 to 20 membered heteroalkyl, substituted or unsubstituted C3-C7 cycloalkyl, substituted or unsubstituted 3 to 7 membered heterocycloalkyl, substituted or unsubstituted C3-C7 aryl, or substituted or unsubstituted 3 to 7 membered heteroaryl; and
R2 is substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted 2 to 20 membered heteroalkyl, substituted or unsubstituted C3-C7 cycloalkyl, substituted or unsubstituted 3 to 7 membered heterocycloalkyl, substituted or unsubstituted C3-C7 aryl, or substituted or unsubstituted 3 to 7 membered heteroaryl.
US Pat. No. 10,306,895

PLANT DEFENSE SIGNALING PEPTIDES AND APPLICATIONS THEREOF

Academia Sinica, Taipei ...

1. A method for inducing systemic immune responses in a plant comprising applying to said plant a plant defense signaling polypeptide comprising a motif of SEQ ID NO: 1 or SEQ ID NO: 28, or a composition comprising the polypeptide, wherein the polypeptide has up to 100 amino acids in length.

US Pat. No. 10,283,714

ORGANIC ELECTROLUMINESCENT MATERIAL CONTAINING ALKALINE EARTH METAL BASED METAL-ORGANIC FRAMEWORKS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME

ACADEMIA SINICA, Taipei ...

1. An organic electroluminescent material having a structure of the following General Formula (1),{[M(L)(H2O)x].(H2O)y}n  General Formula (1)
wherein x is between 1 and 4, y is between 1 and 8, n is a positive integer, M is any one selected from a group consisting of beryllium (Be), strontium (Sr), and radium (Ra), and L is selected from a group consisting of a General Formula (2), a General Formula (3) and a General Formula (4):

wherein, R1, R2, R3 and R4 are each independently a carboxylic group;
Y1, Y2, Y3 and Y4 are each independently a carbonyl group;
A1 and A2 are each independently an oxygen atom or a nitrogen atom, when A1 and A2 are nitrogen atoms, A1 and A2 respectively bind with X1 and X2, wherein X1 and X2 are each independently selected from a group consisting of a hydrogen atom, a hydroxyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted carboxylic group, a substituted or unsubstituted ester group, a substituted or unsubstituted alcohol group, a substituted or unsubstituted pyridyl group, a substituted or unsubstituted ether group, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted nitrooxy group; and
R5, R6, R7 and R8 are each independently selected from a group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a cyano group, an alkylthio group, a hydroxyl group, and an alkoxy group.
US Pat. No. 10,274,488

GLYCAN ARRAYS ON PTFE-LIKE ALUMINUM COATED GLASS SLIDES AND RELATED METHODS

ACADEMIA SINICA, Taipei ...

1. A method for fabricating an array of carbohydrates immobilized directly on an aluminum oxide surface of a single aluminum-coated glass slide, the method comprising:(a) immobilizing a plurality of carbohydrates at discrete locations directly and covalently bound to a single underivatized surface of an aluminum-coated glass slide,
wherein the single aluminum-coated glass slide is conductive or semi-conductive of an electrical field,
wherein the single aluminum-coated glass slide comprises an aluminum oxide surface, and each carbohydrate of the plurality of carbohydrates in the array comprises a phosphonic acid functional group, such that each carbohydrate of the plurality of carbohydrates is a phosphonic acid-derivatized carbohydrate, such that each carbohydrate of the plurality of carbohydrates in the array is immobilized by a covalent bond to said aluminum oxide surface, and
wherein the single aluminum-coated glass slide comprises an aluminum oxide layer configured to be in contact with an aluminum layer, which is configured to be in contact with a single glass slide.
US Pat. No. 10,196,447

ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2) ANTIBODY AND METHODS OF USE THEREOF FOR DETECTING VEGFR2 AND FOR INHIBITING TUMOR GROWTH, TUMOR ANGIOGENESIS AND/OR INDUCING CANCER CELL CYTOTOXICITY

Academia Sinica, Taipei ...

1. An isolated antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising VH CDR1, VH CDR2, and VH CDR3, and the VL comprising VL CDR1, VL CDR2, and VL CDR3,wherein:
the VH CDR1, VH CDR2, VH CDR3 comprise the amino acid sequence of SEQ NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively; and the VL CDR1, VL CDR2, and VL CDR3 comprise the amino acid sequence of SEQ ID NO: 9, Asp Ala Ser, and SEQ ID NO: 10 or 73, respectively.